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1   Summary 
Prion diseases, a group of fatal infectious neurodegenerative diseases causing 
Creutzfeldt-Jakob disease (CJD) in humans, bovine spongiform encephalopathy (BSE) 
in cattle, scrapie in sheep and goat and other prion diseases in animals affecting 
public health, are characterized by the accumulation of the pathogenic prion protein 
PrP
Sc
 in the brain. Inhibiting the propagation of PrP
Sc
, the only known part of the
infectious particle, the prion, is believed to cure prion diseases.  
Small molecules that inhibit PrP
Sc
 aggregation, therefore, may provide a
disease-modifying therapy for these diseases, for which only symptomatic treatment 
is expected to be available so far. We have developed anle138b, a novel aggregation 
inhibitor strongly inhibited disease progression in prion-infected mouse. In vitro, I 
utilized the protein misfolding cyclic amplification (PMCA) to indicate that anle138b 
effectively blocked the formation as well as propagation of PrP
Sc
. Furthermore,
anle138b strongly inhibited all prion strains tested including BSE-derived and human 
prions. In vivo, anle138b inhibited PrP
Sc
 accumulation in prion-infected mice, blocked
neuronal cell death and significantly prolonged survival without showing detectable 
toxicity at therapeutic doses. These data suggest that anle138b may hold promise for 
the anti-prion therapy. 
However, I have noticed that monitoring the therapeutic efficacy of anti-prion agents in 
vivo requires large numbers of experimental animals for measuring the levels of 
Proteinase K (PK)-digested PrP
Sc
, termed PrPres, in the harvested brain at different
stages of the entire incubation period. This strategy causes high experimental costs, 
suffering of experimental animals, and is not applicable to clinical trials in humans. 
Therefore, I firstly established a technique termed real-time quaking-induced 
conversion (RT-QuIC) that is reported to reliably diagnose prion disease by amplifying 
tiny amount of PrP
Sc
 in vitro. I had performed several rounds of both pilot studies and
blind tests that detect PrP
Sc
 in cerebrospinal fluid (CSF) of human CJD patients and
successfully discriminate CJD case from other neurodegenative diseases. Remarkably, 
I obtained 100% sensitivity and 100% specificity of diagnosing human CJD with 
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RT-QuIC. Thereafter, I took this approach one further step to establish a system termed 
quantitative RT-QuIC (qRT-QuIC) that allows sensitively monitoring the therapeutic 
efficacy of anle138b by quantifying the PrPres in both brain and urine of treated and 
untreated mice after prion-infection. I found that variations of levels of PrPres in the 
urine corresponded to those in the brain. These findings indicate that directly 
quantifying PrPres in the urine with qRT-QuIC can track prion progression for 
monitoring the efficacy of anti-prion treatment. This suggests that using qRT-QuIC to 
assess therapeutic efficiency of anti-prion compounds by quantifying PrPres in urine is 
feasible. 
  3 
2   Introduction 
2.1   Prion diseases and prion propagation in vivo 
Transmissible spongiform encephalopathies (TSEs), or prion diseases, are a group of 
infectious and lethal neurodegenerative disorders including sporadic 
Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) in 
human, bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep and 
chronic wasting disease (CWD) in deer (Prusiner, 1982). Prion diseases are 
characterized by the accumulation in the central nervous system (CNS) of a β-sheet 
rich and pathogenic protein, PrP
Sc
, which is the only known constituent of prions.
Prion propagation seems to rely on autocatalytic amplification of PrP
Sc
 by converting
the cellular prion protein (PrP
C
), a normal protein that is host-encoded, glycosylated
and poor of β-sheet, to the pathogenic PrP
Sc
 form without the participation of nucleic
acids (Prusiner 1998; Bieschke et al, 2004). The conversion of PrP
C
 to PrP
Sc
 is a
post-translational event and involves a conformational change of the protein 
(Caughey et al, 1997; Pan et al, 1993). To distinguish the PrP
Sc
 isolated from
infectious tissue and is per definitionem associated with the TSE agent on the one 
hand and structurally altered PrP, which has been converted into a relatively 
Proteinase K (PK)-resistant form in vitro, on the other, I refer to the latter as ‘PrPres’. 
After PK-treatment, fully digested PrP
C
 is undetectable in immunodetection. But the
PrP
Sc
 is partial digested to remain PrPres part that is detectable by showing band shift
in Western blotting. Thus, PK-digestion and followed immunodetection are the most 
commonly used approach to distinguish PrP
Sc
 from PrP
C
 when analyzing infected
tissues (Figure 1).  
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Figure 1. Prion disease is characterized by the accumulation of partially 
PK-resistant PrP
Sc
 in the brain. (a) Susceptible animals, e.g., hamster, can be
infected by the brain samples of prion-infected individuals. Large amount of PrP
Sc
accumulations can be found in the brain by immunohistochemistry (IHC). (b) Prion 
transmission is based on the propagation of an abnormal protein PrP
Sc
. This protein
shares the identical primary structure (amino acid sequence) with the normal cellular 
prion protein PrP
C
 that is expressed by the host PRNP gene. However, PrP
Sc
 is
conformationally different from PrP
C
, especially the β-sheet which structure is rich in
PrP
Sc
 but poor in PrP
C
. PrP
C
 is converted into abnormal and infectious confromation
by using PrP
Sc
 as the template. (c) PK treatment can digest entire PrP
C
 but only part
of PrP
Sc
. After PK-digestion, the treated PrP
Sc
, termed PrPres, shows band shifts on
Western blots thus helps to find the prion-contaminated samples. Subject key: G, 
glycosylation on PrP; PK, Proteinase K; D, diglycosylated pattern of PrP; M, 
Introduction 
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monoglycosylated pattern of PrP; U, unglycosylated PrP. 
 
 
2.2   Cell-free conversion models of prions in vitro 
2.2.1   Necessity of establishing prion propagation model in vitro 
Since the misfolding of PrP
C
 into a PK-resistant form PrP
Sc
 causing lethal prion 
disease is widely accepted, the demands of curing prion disease, preventing prion 
transmission and risk assessment of prion contamination in sugery (such as 
transplant), transfusion and food-safety are essential. Investigating prion transmission 
in susceptible animals should be ideal for the mechanism of prion propagtion. 
However, in vivo assay is time-consuming and expensive. For example, studies of 
prion diseases invariably demonstrate that the prolonged and silent duration of 
incubation may exceed 50 years in human (Collinge et al, 2006) and 15 years in cattle 
(Casalone et al, 2004) before developing clinical features. Although rodent and 
primate models have already been well established, the issue of time-consume is still 
remaining, e.g., 150 – 190 days post inoculation (dpi) in mouse (Castilla et al, 2008). 
In other words, supporting the works of screening anti-prion drug condidates from a 
huge library (may exceed 10 000 types of structure) or diagnosing prion disease with 
several months is unacceptable. Thus, establishment of techniques to examine the 
prion propagation with shorter incubation time is essential.  
 
 
2.2.2   Protein misfolding cyclic amplification (PMCA) 
One theoretical consideration of solving the matter of costs is the in vitro generation of 
prions. The possibility of using cell-free conversion to amplify PrP
Sc
 in vitro has been 
shown (Caughey, 2000; Wong et al, 2001). Further, a more rapid and efficient 
technique termed protein misfolding cyclic amplification (PMCA), was established by 
Soto’s group (Saborio et al, 2001) to amplify prions in vitro. PMCA technique is 
characterized by spiking samples containing PrP
Sc
 seed into normal brain 
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homogenate substrate followed by subjecting this mix to periodic ultra-wave 
sonication and incubation. In PMCA reaction, PrP
Sc
 seed works as a template to
convert PrP
C
 of normal brain homogenate into new PrP
Sc
 to realize a PCR-like
amplification. The PMCA product can be PK-digested for detecting newly formed 
PrPres with immunodetection. But repeated sonication and incubation will cause the 
activity loss of PrP
C
 substrate before the low amount of PrP
Sc
 seed reaches
detectable level. In this case, PMCA products can be subsequently spiked into fresh 
brain homogenates for the next round of PMCA reaction. If this procedure is repeated 
serially, it is termed serial PMCA (sPMCA) (Figure 2). The principle of sPMCA is 
similar to passaging virus in cell culture, except that brain homogenate substrates are 
used in every round. Proceeding sPMCA with fresh brain substrate can retain the 
efficiency of PrP
Sc
 amplification. The product of each round should be harvested for
detecting PrPres till obtaining a reliable amplification. With sPMCA, tiny amount of 
PrP
Sc
 can be amplified to reach the high level. This technique can facilitate to detect
PrP
Sc
 in those samples such as blood and urine (Castilla et al, 2005;
Gonzalez-Romero et al, 2008) containing low amount of PrP
Sc
 that cannot be found by
direct immunodetection or a single round of PMCA. More importantly, due to the use 
of healthy brain homogenates of susceptible animals as the substrates that contain 
most of the brain components, e.g., PrP
C
, lipids and other cofactors, sPMCA is
effective to mimic the prion propagation in the brain. Inoculating susceptible animals 
with sick brain and sPMCA products respectively, the comparable infectivity, clinical 
signs and pathological features were observed (Bieschke et al, 2004; Castilla et al, 
2005). Regarding the comparison of sensitivities, the half lethal dose (LD50) of the 
diluted brain from terminal ill animal is commonly 10
-7
-10
-8
 g (Saá et al, 2006;
Browning et al, 2011), but sPMCA can allow PrP
Sc
 propagating even the originally
seeded brain is highly diluted, e.g., 10
-40
-fold (Castilla et al, 2005). Normally, 1 g of
brain from terminal ill animal contains 10
-5
 to 10
-6
 g of PrP
Sc
, and the weight of 1 PrP
molecule is ~ 10
-19.42
 g (molecular weight of PrP is ~23 kDa). Thus, 1 g of brain
contains 10
13.42
 to 10
14.42
 PrP
Sc
 molecules. Mathematically, only one PrP
Sc
 molecule is
left in 10
-13.42
 to 10
-14.42
 g of brain. The sPMCA samples containing sick brain lower
than 10
-14.42
 g does not have any brain-derived PrP
Sc
. The biological properties of
PrP
Sc
 in such sPMCA product, including infectivity, PK-resistance and conformational
feature are from in vitro formed but not brain-derived PrP
Sc
 (Castilla et al, 2005; Saá et
al, 2006), indicating that the PrP
Sc
 amplification in PMCA (also in sPMCA) is a good
Introduction 
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model to study the PrP
Sc
 propagation in vivo (Figure 3).
Figure 2. The PCR-like amplification of PrP
Sc
 in PMCA and the cell culture-like
passage in sPMCA. PrP
Sc
 can amplify itself by using brain homogenates containing
PrP
C
 substrate. PMCA products are spiked into fresh preparations for serially
generating PrP
Sc
 in sPMCA. Final products of sPMCA lacking of brain-derived PrP
Sc
can still infect susceptible animal, e.g., hamster. Thus, PMCA and sPMCA are both 
effective tools of investigating prion propagation in vitro. The amplification of PrP
Sc
 in
PMCA is estimated by detecting PrPres in Western blotting after PK-digestion. Subject 
key: R, round, one PMCA reaction before spiking products into a fresh substrate for 
the next PMCA is called one round. 
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Figure 3. sPMCA mimics prion propagation and transmission in vitro. (A) 10% 
brain homogenates (brain weight divided by homogenate volume, w/v) of terminal ill 
hamster infected by prion-strain 263K was 10-fold diluted into 10% normal hamster 
brain homogenates (w/v) for the first round of PMCA. One reaction was 100 μl 
containing 10 μl of 263K brain homogenate and 90 μl of normal brain homogenate. 
One round of PMCA was performed at 37
o
C for 48 h. Thereafter, 10 μl was spiked into 
90 μl of freshly prepared normal hamster brain homogenates. From the round 4, 1 μl 
of product of the last round was 100-fold diluted into 99 μl of fresh normal brain 
homogenate followed by performing PMCA at 37
o
C for 48 h. This step is repeated 
several times till the original 263K brain reaching 10
19
-fold dilution. (B) The products 
(10
19
-fold dilution) are spiked 100-fold into brain homogenates of Tg81 mouse, a 
transgenic model expressing hamster PrP
C
, for a new round of PMCA. This is 
repeated several times till the original hamster 263K brain is 10
31
-fold diluted. (C) This 
product is 100-fold diluted in normal hamster brain homogenates to perform several 
rounds of PMCA till the original hamster 263K brain is 10
43
-fold diluted. In every round 
of PMCA shown in A, B and C, PrPres is consistently detected in 10 μl of product after 
PK-digestion and Western blotting, indicating 263K PrP
Sc
 can endlessly amplify in 
either hamster or Tg81 brain. These results are similar to in vivo transmission of 263K 
Introduction 
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prion from infected hamster to either the healthy hamsters or Tg81 mice (right panels). 
Therefore, sPMCA mimics the transmission of prions in vitro (figures are unpublished 
results). 
By using PMCA technique, prion researchers can apply various conditions to study 
the crucial hypothesis about prions, the ‘Protein-only’ hypothesis (Prusiner, 1998), 
which means PrP
Sc
 of mammalian is the only infectious component during prion
transmission, was demonstrated by serial studies. This means, PMCA can be utilized 
to not only investigate potential factors that can enhance the prion propagation 
(Deleault et al, 2003; Deleault et al, 2007; Wang et al, 2010), but also find those 
factors that can disturb amplification, suggesting a possibility of using PMCA to screen 
anti-prion drug-like candidates. Given these advantages, my lab chose PMCA to 
select anti-prion compounds by testing their abilities to inhibit PrP
Sc
 amplification in
vitro before estimating their therapeutic efficacies in bioassays. 
Another important part in prion field is the sensitive detection and quantification of 
prions during the incubation period of prion infection. The outcomes are able to 
suggest suitable diagnostic systems for medicine and biosafety. Despite authentic 
ability of amplifying PrP
Sc
, PMCA does not fulfill the requirement of rapid diagnosis of
prions. This technique is still limited by its sensitivity, time-span and source of 
substrate, which factors affect the validation of clinical diagnosis. For example, PMCA 
of 72 h can sensitively detect PrP
Sc
 in 10
-6
 to 10
-8
 g of brain from terminally ill animals
(Chen et al, 2010), but PMCA reaction exceeding 72 h may induce the spontaneous 
conversion of PrP
C
 into PK-resistant and infectious agent thus generates de novo
prions (Barria et al, 2009). One possible solution for this ‘72 h cut-off’ is to use sPMCA 
but it also shows the obvious shortages for prion diagnosis. For performing sPMCA by 
rounds, the repeated pipetting from one passage to another is essential (Morales et al, 
2012). However, this procedure may require continuous amplification of several 
weeks with repeadedly opening caps and pipetting liquids. This increases the risk of 
generating aerosol that may cause cross-contamination, and decreases the 
applicability of estimating large-scale of suspected samples while treating PMCA 
products with PK and detecting PrPres with immunodetection (Western blotting, dot 
blotting and ELISA). In addition, the source of PMCA substrate must be from the brain 
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of the same species or transgenic models so that PMCA is only performed in special 
lab but not packed in a kit for the validation of clinical prion diagnosis.  
2.2.3 Real-time quaking-induced conversion (RT-QuIC) 
To address the requirement of detecting prion with a rapid and high-throughput assay, 
a novel technique, termed Real-time quaking-induced conversion (RT-QuIC), was 
established. RT-QuIC can detect prions with very high sensitivity from diluted brain 
(Wilham et al, 2010), from cerebrospinal fluid (CSF) of end-stage disease containing 
only very low levels of infectivity (Atarashi et al, 2011; McGuire et al, 2012; Peden et al, 
2012), and from CSF during the incubation period (Orrù et al, 2012). The mechanism 
of RT-QuIC is based upon the seeded PrP
Sc
 converting PK-sensitive recombinant
prion protein (rPrP) into a PK-resistant rPrP (rPrPres) form, which is rich in -sheet 
structures. This reaction is performed with periodic shaking (Figure 4) and the result 
of amplified PrP
Sc
 is shown with the increased fluorescence that is caused by the
-sheet of newly formed rPrPres bound with Thioflavin T (ThT), a dye that efficiently 
binds to the -sheet structure on the proteins (Figure 5). The correlation between ThT 
fluorescence and rPrPres has been shown and is used to monitor the conversion in a 
real-time curve (Atarashi et al, 2011).  
Figure 4. PrP
Sc
 amplifies in RT-QuIC system. PrP
Sc
 is spiked into a preparation
containing rPrP substrate followed by subjecting to RT-QuIC for periodic shaking. rPrP 
is converted by PrP
Sc
 into rPrPres so that PrP
Sc
 is amplified.
Introduction 
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Figure 5. Thioflavin T (ThT) binds the β-sheet of protein. ThT dye binding to the 
β-sheet of protein can be detected by fluorescence with 440 nm of excitation and 480 
nm of emission. Thus, newly formed rPrPres that is β-sheet rich can be detected by 
ThT-binding in RT-QuIC reaction. 
 
 
RT-QuIC overcomes the problems of PMCA/sPMCA. First, comparing the sensitivity 
of a single round of PMCA that detects 10
-6
 to 10
-8
 g of prion-infected brain, the single 
round of RT-QuIC has higher sensitivity that can detect minimal 10
-15.5
 g of 
PrP
Sc
/PrPres (Shi et al, 2013) coming from 10
-10
 g of brain. Second, RT-QuIC is 
performed in a plate, e.g., 96-well, with tape-seal on each well, and the read-out is 
displayed directly by monitoring the ThT-fluorescence with automated processing and 
software analysis. Thus, it is no longer necessary to harvest the products for further 
PK-digestion and immuodetection, minimizing the risk of aerosol cross-contamination 
and decreasing the intensity of work, fulfilling the requirement of high-throughput 
screening. Third, RT-QuIC applies bacterially expressed rPrP as the substrate which 
is easily obtained, optimized and packed, suggesting the availabilities of spreading 
RT-QuIC to common clinical validation, food-safety assay, assessment of blood 
product and scale-up industrialization. Given these advantages above, RT-QuIC is 
superior to PMCA for prion diagnosis. 
 
ThT-binding fluorescence directly indicates -sheet structure in the solution. For 
keeping both efficiencies of excitation and emission, the tested solution should be 
clean and transparent. Therefore, RT-QuIC cannot be performed in a muddy solution 
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such as brain homogenate containing potential cofactor that may play roles in the 
misfolding of brain-derived PrP
C
 to PrP
Sc
, indicating that RT-QuIC is not an authentic
in vitro model to mimic prion propagation in the brain. Here we chose RT-QuIC only for 
sensitive detection of PrP
Sc
 but not for selecting anti-prion candidates.
2.2.4 Quantitative RT-QuIC (qRT-QuIC) 
Although protease-resistant PrPres is often used as a definitive biological marker for 
TSE infection, the titer of infectivity measured by inoculation in experimental animals 
does not always fully correlate with the amount of PrPres detected by Western blotting. 
The correlation of seeding activity on rPrP conversion into rPrPres measured by 
RT-QuIC with the amount of PrPres is also a complex issue. For example, it has been 
shown that vCJD prions have less seeding activity than sCJD prions despite the 
relatively high PrPres concentration (Peden et al, 2012), and that prions from brains of 
hamster prion-strain 263K-affected mice with little western blotting-detectable PrPres 
have a seeding activity comparable to that associated with the high-PrP
Sc
 strain,
mouse prion 139A (Vascellari et al, 2012). In previous studies, it has been shown that 
the complex correlation between amounts of PrPres and infectivity in vivo and seeding 
activity in vitro can be explained at least in part by differences in size distribution of 
PrP aggregates (Weber et al, 2008). Consequently, RT-QuIC seeding activity may 
correlate more closely with prion infectivity than with PrPres levels, which can be 
considered an advantage in regard to the development of assays for prions detection. 
I observed that in the RT-QuIC reaction, adding small amounts of PrP
Sc
, or PrPres,
resulted in a delayed initiation of conversion detected by ThT fluorescence (Figure 6). 
These lag-phases and the shape of the resulting ThT fluorescence curve appeared 
similar to the kinetics of amplification of DNA that is used for quantitative RT-PCR 
analysis (Schmittgen et al, 2000; Radonić et al, 2004) (Figure 7). Thus I investigated 
whether real-time protein amplification was quantitative and established a highly 
sensitive assay for the quantification of prion infectivity in a high-throughput system 
based on measuring lag time of detectable conversion. I termed this approach 
quantitative RT-QuIC (qRT-QuIC) and showed that it allows quantitation of prions in 
Introduction 
13 
various tissues with a detection limit corresponding to 0.001 LD50 units. 
Figure 6. Lag phases of RT-QuIC reactions are correlated with the seeded 
amounts of PrPres. RT-QuIC reactions spiked with 10
-12
 to 10
-16
 g of PrPres show
different lag phases of amplification detected by ThT fluorescence in 90 h of process. 
PrP
C
 seeded as controls does not induce positive reaction in 90 h.
Figure 7. Schematic illustrations of qPCR, qRT-QuIC and calibration. The colorful 
lines represent the amplification profiles of DNA (qPCR) and prions (qRT-QuIC). In 
both techniques, the required times (Ct of qPCR and Rht of qRT-QuIC) are recorded 
as the dependent variables x while the fluorescence of amplification reach the 
threshold (represented by intersecting lines). Taking the Rhts and the known amount 
of seeds (y) together can harvest the quantitative calibration. Ct, cycle number to 
threshold in qPCR; Rht, required hours to threshold in qRT-QuIC; RFU, relative 
fluorescence unit  
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2.3   Development of anti-prion compound anle138b 
As mentioned above, prion diseases are a group of fatal neurodegenerative discords 
in humans, cattle, sheep, elk, mink and experimental animals. These diseases are 
characterized by neuronal death and the accumulation of pathological 
disease-associated prion protein (PrP
Sc
) in the central nervous system (Prusiner, 
1998). a recent large-scale epidemiological study indicates that the potential hosts of 
variant CJD (vCJD) are far more than the count of previous survey (1 out of 2000 in 
UK) (Gill et al, 2013), suggesting that prion diseases remain the threats of public 
health.  
 
Developing drug-like candidates for curing prion diseases remains to be the major 
task in the field of prion researches (Mallucci and Collinge, 2005; Harrison, 2013). A 
crucial role of PrP
Sc
 aggregates in disease pathogenesis is suggested by abundant 
evidence including i) the consistent detection of PrP
Sc
 deposits in affected brain areas 
of human and animals, ii) pathogenic mutations on the PRNP gene that encodes 
cellular PrP (PrP
C
) affecting the human familial prion diseases and association of the 
PrP
Sc
 locus with idiopathic prion diseases, such as fatal familiar insomnia (FFI) and 
familiar Creutzfeldt-Jakob disease (fCJD), iii) the epidemiological studies of the 
transmissions of Kuru and BSE, iv) experimental evidence in vitro, in cell culture, and 
in animal models that PrP
Sc
 acts both as a template for this conversion and as a 
neurotoxic agent causing neuronal dysfunction and cell death (Prusiner, 1998; 
Collinge, 2001). Therefore, PrP
Sc
 is not simply the biomarker of diagnosing prion 
diseases, more importantly, it is also the target for anti-prion therapy. Targeting 
neurotoxic protein aggregates may thus provide a therapeutic strategy for causal 
treatment of these devastating diseases and other protein aggregation disorders. 
 
PMCA is a technique developed for investigating prion propagation in vitro. Due to the 
similarities of biochemical and infectious features of PMCA-derived PrP
Sc
 and brain 
brain-derived PrP
Sc
 (Castilla et al, 2005), we chose PMCA to characterize available 
candidates for in vivo anti-prion therapy.  
 
Introduction 
 
 
 
15 
Recently, we have introduced an efficient and non-toxic anti-prion compound, named 
anle138b, which was capable of significantly prolonging the survival time by inhibiting 
prion propagation and aggregation (Wagner et al, 2013). In this study, I applied PMCA 
to investigate the anti-prion abilities of inhibiting PrP
Sc
 amplification by performing the 
reactions containing normal brain homogenate substrates, prion-infected brains and 
different synthetic compounds. By using PMCA, I found that anle138b compound 
effectively inhibited the propagation of mouse prion-strain RML. Further in vivo tests 
by feeding RML-infected C57BL/6 mice with anle138b starting at 80 dpi (days post 
inoculation) resulted in 250 dpi of prion incubation period, which was 80 days longer 
than 170 dpi of untreated controls. To assess the anti-prion therapeutic efficacy of 
anle138b, the brains of both treated and untreated mice were harvested at different 
time points of prion infection for detecting the levels of PrPres using 
immunohistochemistry, PK-digestion and Western blotting. I found that brain PrPres of 
anle138b-treated mice at 80, 120 and 170 dpi was much less than those in untreated 
mice. Furthermore, I found that anle138b inhibited propagation of not only the mouse 
scrapie prion strains RML and ME7, but also the mouse-adapted BSE strain 301C. 
More importantly, anle138b was found to inhibit the propagation of human 
brain-derived sCJD and vCJD in PMCA, suggesting the clinical validation of treating 
human CJD cases with anle138b. Given the comparability between in vitro amplifying 
prions with PMCA and in vivo assay with animal models, anle138b performs as an 
ideal anti-prion candidate for neutralizing prion diseases. 
 
 
2.4   Monitoring anle138b treatment with qRT-QuIC 
Detecting PrPres (PK-resistant PrP
Sc
 fragments after proteolysis) in the brains of 
different stages of prion disease is widely accepted for estimating anti-prion therapeutic 
treatment in experimental animals. This is applied not only in the study about anle138b 
compounds, but also in many studies which also investigated anti-prion through 
developing compounds and antibodies (Korth et al, 2001; White et al, 2003; Doh-ura et 
al, 2004; Mallucci and Collinge, 2005; Kawasaki et al, 2007; Wagner et al, 2013). 
Although all of these studies are impressive and compelling, it should be noticed that 
monitoring anti-prion therapy by detecting PrP
Sc
 or PrPres in those harvested brains is 
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laborious with highly costs, e.g., for testing one compound, we applied at least 12 mice 
for the treated group and additional 12 mice for the untreated at each dpi, even though 
the library of compounds could be narrowed down as much as possible by using PMCA. 
Moreover, harvesting brains is not applicable for further clinical tests in humans. It is 
noteworthy that infectious prions in CNS affect the use of normal clinical diagnostic 
techniques, e.g., radiography and biopsy, due to either biohazard risk or irreversible 
injury to the patients. Monitoring the disease progression and the efficacy of treatment 
with competent molecular technique has not been achieved. Therefore, I aimed at 
finding a better way, which should facilitate tracking prion progress in living 
experimental animals and humans. RT-QuIC has been shown to have both high 
sensitivity and specificity for detecting PrP
Sc
 in brain and CSF. In particular, RT-QuIC 
can be used to rapidly diagnose human CJD in the CSF (Atarashi et al, 2011; McGuire 
et al, 2012), although PrP
Sc
 in human CSF is very low and the CSF is only weakly 
infectious (Brown et al, 1994). Given both sensitivity and specificity of RT-QuIC of 
detecting PrP
Sc
 in vitro, as well as the high-throughput qRT-QuIC of quantifying PrPres 
in peripheral tissues (Shi et al, 2013), I chose qRT-QuIC to quantify the PrPres in 
easy-obtainable biological material, e.g., urine, to monitor the efficacy of anti-prion 
therapy. 
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3 Materials and Methods 
3.1 Preparing brain homogenates for screening anti-prion 
compounds with PMCA 
Frozen mouse-adapted BSE (strain type: 301C) and mouse-adapted scrapie (strain 
type: RML and ME7) brains and human sporadic CJD (sCJD) and variant CJD (vCJD) 
brain samples were homogenized in pre-chilled PMCA conversion buffer, containing 
1-fold PBS, 1% Triton X-100, 5 mM EDTA, 150 mM NaCl and protease inhibitor 
cocktail tablets (Roche, Basel, Switzerland). Crude 10% (w/v) homogenates were 
centrifuged with 2,000 x g at 4
o
C for 10 s. Aliquots of the supernatant were
immediately frozen at -80°C for subsequent experiments. Whole normal mouse brains 
were obtained from 10-week-old C57BL/6 mice. After homogenization in pre-chilled 
PMCA conversion buffer, 10% (w/v) normal brain homogenates were centrifuged at 
2,000 × g for 10 s, and aliquots of the supernatant were frozen at -80°C till used as the 
substrate for amplifying mouse-adapted prions. Frozen cortex harvested from 
non-CJD human brain was homogenized and stored as above for amplifying human 
CJDs.  
3.2 Screening anti-prion compounds with PMCA reaction 
PMCA was performed in a water-bath sonicator (Misonix sonicator 3000, Misonix, 
Farmingdale, NY, USA), which had a microplate horn for PCR tubes. Normal brain 
homogenate was spiked with infected brain homogenate (100:1, v/v) and 99 µl of this 
mixture was transferred into 0.2-ml PCR tubes which contained 1 µl of DMSO or 
compound solved in DMSO. Eighteen PMCA cycles for mouse substrates and 40 
cycles for human substrates were performed. Each cycle consisted of sonication at 
60% potency (~209 W) for 20 sec followed by incubation at 37 ºC for 59 min 40 sec. 
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3.3   Western blotting for testing PMCA product 
PMCA product was digested with 50 µg/ml proteinase K (PK) at 37 ºC for 1 h. After 
adding an equal volume of 2×SDS loading buffer and boiling for 10 min, samples were 
separated by SDS-PAGE of 15% gel followed by transferring to PVDF membranes 
(Immobilon-P, Millipore, MA, USA) at 12 V for 2 h. For western blotting, the membrane 
was blocked with 5% nonfat milk in PBST. Mouse-derived PrP was detected by 
1:5000 diluted 4H11 monoclonal antibody (Herms et al, 1999) and human-derived PrP 
was detected by 1:5000 diluted 3F4 monoclonal antibody (Dako, Glostrup, Denmark) 
in 1 fold PBST at room temperature for 2 h. After three washes in 1 fold PBST, the 
membrane was immerged in a 1:5000 diluted alkaline phosphatase conjugated 
goat-anti-mouse IgG (Dako) in 1 fold PBST and incubated at room temperature for 2 h. 
Detection was performed with CDP-Star solution (Roche, Mannheim, Germany).  
Western blottings were scanned and quantified by a Diana III luminescence imaging 
system along with the AIDA software package (Raytest, Straubenhardt, Germany). 
 
In Western blots shown in results section, “start” indicates the sample taken from the 
PMCA reaction mixture at time point 0 after mixing normal brain homogenate with a 
minute amount of PrP
Sc
 that acts as a seed for the subsequent PMCA reaction. Thus, 
this sample provides the reference for screening drug-like candidates which following 
PMCA incubation contain different amounts of newly formed PK-resistant PrPres 
depending on the different efficacy of prion amplification during PMCA. Thus, this 
assay design (comparison of time points before and after PMCA amplification) does 
not require a “loading control”. Due to load identical volumes of 10% brain 
homogenates after PK-digestion, this assay does not need a house-keeping gene 
encoded protein control such as α-tublin and β-actin.  
 
3.4   Experiments in prion-infected mice for screening anti-prion 
compounds 
For screening and structure-activity analysis, compounds were tested in regard to 
their inhibitory effect on PrP
Sc
 accumulation in vivo by three experimental protocols:  
a)  Seven-week-old female C57BL/6 mice were inoculated intracerebrally (i.c.) with 
Materials and Methods 
19 
30 µl of 1 % (w/v) brain homogenate (RML scrapie). Treatment was started at 80 
days post infection (dpi) with 1 mg compound per day mixed with 10 µl of DMSO 
+ 200 µl of peanut butter applied orally. PrP
Sc
 level in the brain was measured at
120 dpi by western blotting analysis.  
b) Seven-week-old female C57BL/6 mice were inoculated intraperitoneally (i.p.) with
100 µl of 1 % (w/v) brain homogenate (RML scrapie). PrP
Sc
 level in the spleen
was determined at 35 dpi following 34 days of treatment with 1 mg compound
mixed with 10 µl of DMSO + 200 µl of peanut butter per day.
c) Seven-week-old female C57BL/6 mice were inoculated i.c. with 30 µl of 1 % (w/v)
brain homogenate (RML scrapie). Treatment was started at 80 dpi with 0.84 mg
compound (in 25 µl of DMSO) per day applied by intraperitoneal injection for 14
days followed by 2 x 5 days (with 2 days without treatment in between) of 1 mg
compound (in 10 µl of DMSO + 40 µl of vegetable oil) applied orally by gavage.
PrP
Sc
 level in brain was measured at 106 dpi.
For long-term survival experiments, anle138b was administered orally in 
DMSO/peanut butter as described above. In a first set of experiments, 5 mg anle138b 
were given once daily starting either at day 80 or day 120 post i.c. infection. Animals 
of each treatment group were monitored daily for signs of disease by trained animal 
caretakers from day 80 post infection. The animals were sacrificed, when they had 
reached the terminal stage of the disease based on clinical signs (ataxia, tremor, 
difficulty in righting up from a position lying on its back, and tail stiffness). Typically the 
disease progress through the terminal stage will lead to the death of the animal within 
one or two days. From all animals one brain hemisphere and one half of the spleen 
were freshly frozen at -80 °C for biochemical analysis. The other hemisphere and the 
remaining half of the spleen as well as all inner organs were fixed in 4% formaldehyde 
solution for histological analysis. In a further experiment, treatment with anle138b was 
started on the day of i.c. infection with a dose of 5 mg anle138b twice daily. The in vivo 
experiments used for comparison with PMCA results were mainly performed by Dr. 
Jens Wagner as a part of his doctoral thesis. 
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3.5   Histology and immunohistochemistry for screening 
anti-prion compounds 
Prion infectivity was inactivated by immersion in 100% formic acid (Brown et al, 1990). 
Paraffin-fixed sections (2.5 µm) of brain tissue were stained with H&E. For PrP
Sc
 
detection using monoclonal antibody CDC1 (Pfeifer et al, 2006), sections were 
immunostained on a Ventana automated staining apparatus. To assess neuronal 
degeneration, neurons with pyknotic nuclei were counted in blinded slides in the 
cerebellar granule cell layer. This approach has been validated previously as an 
efficient measure for apoptotic neuronal cell death (Giese et al, 1995). For each 
animal, 30 randomly chosen high power visual fields were analyzed.   
 
3.6   Quantifying the PrPSc of anti-prion treated and untreated 
mice 
For quantification of PrP
Sc
, brain homogenates were homogenized 10 % (w/v) in lysis 
buffer (100 mM NaCl, 10 mM EDTA, 0.5 % (v/v) NP-40, 0.5 % (w/v) deoxycholate, 10 
mM Tris/HCl pH 7.4) and subjected to dot blot analysis using 6H4 monoclonal 
antibody (Prionics, Switzerland) at a dilution of 1:5000. For PrPres western blotting, 
infected brain homogenates were treated with PK (100 µg/ml, 1h, 37
o
C) prior to dot 
blot analysis. Spleens were homogenized in Dulbecco’s PBS 10 % (w/v) and PrP
Sc
 
was precipitated from 500 µl of homogenates using sodium phosphotungstic acid 
(NaPTA) as previously described (Wadsworth et al, 2001). Pellets were resuspended 
in 20 µl of 0.1 % sarkosyl buffer and treated with PK (50 µg/ml, 1 h, 37 °C). PrPres 
was visualized with CDP-Star detection reagent (Roche, Mannheim, Germany). 
Quantification was performed using a Diana III luminescence imaging system along 
with the AIDA software package (Raytest, Straubenhardt, Germany). The relative 
inhibition of PrP
Sc
accumulation compared to DMSO-treated groups was calculated as 
follows:   
% inhibition = (1- (x-s)/(c-s))*100  
x = amount of PrPres in compound-treated group at end of treatment period  
s = amount of PrPres in control group at start of treatment period  
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c = amount of PrPres in control group at end of treatment period 
 
3.7   Sucrose-gradient assay 
Sucrose-gradient assay was performed as described elsewhere (Tzaban et al, 2002) 
with minor modifications. Briefly, 10% brain homogenates (w/v) were prepared using 
1×PBS (pH 7.2) containing 0.1% NP-40 with protease inhibitor cocktail EDTA-free 
(Roche, Switzerland) and were stored at -80°C without centrifugation. Before further 
processing, samples were thawed on ice. To obtain a 1% (w/v) brain homogenate 
1×PBS containing 0.5% sodium deoxycholate and 1% sarcosyl was added. Then 
samples were agitated with 1200 rpm at 4°C for 30 min (Thermomixer Comfort, 
Eppendorf, Germany). To discard debris, samples were centrifuged with 20,000 × g at 
4°C for 1 min. To prepare a sucrose-gradient solutions containing 10 mM Tris (pH 7.2), 
1% sarcosyl and sucrose (10%, 20%, 30%, 40%, 50% and 60%, respectively) were 
filled into a 4 ml 11×60 mm polyallomer tube (Beckman coulter, USA) beginning with 
200 μl of 60% sucrose solution loaded to the bottom, followed by adding 400 μl of 
50% to 10% sucrose, respectively. For the last loading, 200 μl brain homogenate was 
gently tiled on the top of the 10% sucrose. Ultracentrifugation with 100,000 × g at 4°C 
for 1 h was performed using a Sw60Ti rotor (Beckman coulter, USA). Samples for 
Western blotting were harvested after centrifugation from the top to the bottom of the 
sucrose-gradient in 200 μl of fractions (i.e. fraction 1 represents the top of the gradient 
and fraction 12 the bottom fraction). For analyzing size-distribution of PrPres, fractions 
from the sucrose-gradient were digested by 50 µg/ml PK at 37°C for 1 h. Reaction 
was stopped by adding 2× SDS loading buffer and boiling at 100°C for 15 min for 
Western blot assays as described in section 3.3.  
 
3.8   rPrP expression and purification for RT-QuIC and qRT-QuIC 
BL21 (DE3) E.coli. and pET41a system (Merk, Germany) were used to express 
full-length rPrPs of human, hamster, mouse and sheep. Bacteria were cultured in LB 
medium at 37
o
C with 220 rpm shaking and were added 1 mM of IPTG (final 
concentration) when OD reached 0.7 to 0.9. The cell pellet was harvested by 10,000 g 
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centrifugation at 4
o
C for 10 min after 4 hours of induction. Thereafter, cells were
resuspended in BugBuster Master Mix (Novagen, Germany) containing rLysozyme 
and Benzonase to extract inclusion bodies (manual for BugBuster, Novagen, 
Germany). Extracted inclusion bodies were denatured with 8 M Guanidine 
hydrochloride at 25
o
C for 1 hour. The denatured protein solution was centrifuged at
16,000 g at 4
o
C for 20 min to remove the debris.
I chose Ni
2+
-NTA superflow (Qiagen, Germany) resin for protein purification. NTA resin
was prepared by following the manufacturer’s manual. The denatured protein was 
loaded onto prepared resin followed by binding with inversion on the rotor at 25
o
C for
1 hour. After that, the resin was loaded into the column (GE Healthcare, USA) 
followed by connecting to the AKTA prime (GE healthcare, USA). Purification 
procedures including refolding and elution for preparing hamster, mouse and sheep 
rPrP were followed the methods described elsewhere (Atarashi et al, 2008). 
Purification of human rPrP was a novel method that has been filed a patent 
application (Song Shi, Armin Giese and Hans Kretzschmar, Method for the isolation of 
recombinant prion protein and the use thereof, EP 13182421.1). 
After elution, the rPrP solution was loaded into 6 kDa Cellu Sep dialysis tubing 
(Interchim, France) followed by immersion in pre-chilled dialysis buffer (9 mM 
NaH2PO4, 1 mM Na2HPO4, pH 5.9) at 4
o
C. The dialysis was done in 2 successive
steps, which were 2 hours and 18 hours, respectively. 100 volumes of dialysis buffer 
were used for each step. The dialyzed solutions were sterilized with a 0.22 μm filter 
(Millipore, USA) and the absorption was measured at 280 nm for calculating the 
concentration of rPrP. The concentration of each fraction was adjusted to 0.5 mg/ml 
by adding sterilized and chilled dialysis buffer. The rPrP solution was aliquoted and 
frozen in liquid nitrogen, followed by transfer to a freezer (-80
o
C) for long-term
storage. 
3.9 Brain preparation for RT-QuIC 
Brain samples of human sCJD and vCJD, cattle classic type BSE (C-BSE) and 
low-type BSE (L-BSE), normal human and normal cattle were prepared as 10% brain 
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homogenates as described in section 3.2.1. Thereafter, these brain homogenates 
were serially 10-fold diluted by using 1×QuIC-PBS (pH 7.2) containing 130 mM NaCl, 
5 mM NaH2PO4, 5 mM Na2HPO4 and 1 mM EDTA. Preparations were aliquoted and 
frozen at -80
o
C till being used as the seeds.
3.10 Human CSF samples for RT-QuIC 
For the pilot study, human CSF samples were collected in our institute within the 
framework of the German national CJD surveillance study. Coded CSF samples were 
obtained from both definite CJD and non-CJD patients with confirmatory assays of 
detecting pathological changes and PrP
Sc
 deposits in the brains by histology and
immunochemistry, as well as PrPres by Western blotting. Within an international 
collaboration, blindly prepared human CSF samples were sent from Dr. Alison 
Green’s group (National Creutzfeldt-Jakob Disease Research & Surveillance Unit, 
NCJDRSU, Western General Hospital, University of Edinburgh, UK).  
3.11 RT-QuIC reaction 
The RT-QuIC reactions were performed in the volume of 100 μl containing (final 
concentrations after seeding) 400 mM NaCl, 5 mM NaH2PO4, 5 mM Na2HPO4, 1 mM 
EDTA, 100 μM thioflavin T and 100 μg/ml rPrP (pH 7.2) in a Nunc 96-well plate 
(Thermo Scientific, USA). These ingredients were first prepared as a master mix 
preparation (90 μl for each reaction) before adding 10 μl of seeds (brain and CSF). 
Before incubation, the plate was sealed carefully with transparent tape for avoiding 
cross-contamination and aerosol formation. Reactions were performed on a FLUOstar 
Optima (BMG Labtech, Germany) at 42
o
C for 90 hours with 1 min shaking at 600 rpm
followed by 1 min stationary incubation. The fluorescence was measured with bottom 
optic every hour. The excitation was 440 nm, emission was 480 nm and the gain 
setting was 2000. The whole procedure was controlled by a programmed Script Mode 
(this edited mode is a gift from Dr. Byron Caughey, NIAID, NIH). Curves were directly 
shown by the provided functions of BMG Optima Data Analysis software.  
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3.12   Tissue preparation for qRT-QuIC 
6-week old C57BL/6 mice were inoculated with mouse-adapted RML and ME7 scrapie 
(i.c). 10 μl of 10% brain homogenate in 1×PBS (pH 7.2) was used for each inoculum. 
7 time-points (30, 60, 90, 120, 135, 150 and 170 dpi, days post inoculation) were set 
for RML-infection and 6 time-points (30, 60, 90, 120, 135 and 150 dpi) were for 
ME7-infection. At each dpi, five mice were sacrificed with CO2. To harvest the tissues 
(brain, heart, liver, spleen, lung, kidney and hindlimb muscle) they were washed with 
chilled 1×PBS containing 5% sodium citrate to remove the blood. Then tissues were 
weighed and stored in liquid nitrogen. The tissues of age-related control C57BL/6 
mice were prepared following the same procedure.  
3.13 PrPres purification for qRT-QuIC 
I followed a published protocol (Polymenidou et al, 2002) to purify PrPres. RML- and 
ME7-infected mouse tissue was prepared to 10% homogenate (w/v) with lysis buffer 
(pH 7.2) containing 130 mM NaCl, 10 mM NaH2PO4, 10 mM Na2HPO4, 0.5% Triton 
X-100, 0.5% sodium deoxycholate, 2 mM MgCl2, 2.5 U/ml of Benzonase (Merck, 
Germany) and EDTA-free protease inhibitor cocktail (Roche, Switzerland). 
Homogenate was incubated at 25
o
C for 30 min for digesting nucleic acids followed by
1,000 g centrifugation at 4
o
C for 5 min for removing debris. Thereafter, 100 μl of
supernatant were doubly diluted with lysis buffer to reach 200 μl of total volume 
followed by 20 μg/ml of PK-digestion at 37
o
C for 1 h. The digestion was stopped by
adding 5 mM PMSF (Sigma-Aldrich, Switzerland) and the PK-treated supernatants 
were transferred into 300 μl of 1×QuIC buffer (130 mM NaCl, 5 mM NaH2PO4, 5 mM 
Na2HPO4 and 1 mM EDTA, pH 7.4). The total volume reached 500 μl. 
The preparations were then brought to equal volume of buffer containing 20% NaCl 
and 0.1% sarkosyl. These solutions were vortexed vigorously followed by incubating 
on ice with gentle shaking for 10 min. After centrifugation at 16,000 g at 4
o
C for 10 min,
the pellets were washed by 500 μl of 20 mM Tris-HCl containing 0.05% sarkosyl 
followed by 16,000 g of centrifugation at 4
o
C for 10 min. This washing step was
repeated twice. The pellet was stored at -80
o
C till being used as the seed.
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For preparing the prion seeds, the frozen pellets were thawed at 4
o
C followed by 
washing with 500 μl of ddH2O. The resuspended solutions were precipitated by 
centrifugation at 16,000 g for 10 min at 4
o
C. This step was repeated twice. The last 
pellets were resuspended thoroughly by 50 μl of ddH2O followed by 1,000 g of 
centrifugation at 4
o
C for 1 min. 45 μl of supernatant from peripheral tissues (tissue 
extract) was brought to qRT-QuIC to be both the seed and required water. Ten μl of 
PrPres with known concentration quantified by WB was used as the seed for obtaining 
a standard calibration curve. 
 
3.14   PrPC purification for qRT-QuIC 
We referred to a published protocol (Deleault et al, 2007) to purify mouse PrP
C
. The 
brain from a healthy 20-week old C57BL/6 mouse was homogenized in chilled 1×PBS 
(pH 7.2) containing EDTA-free protease inhibitor cocktail (Roche, Switzerland) to 
make a 10% homogenate (w/v). After centrifugation at 3,000 g at 4
o
C for 30 min, the 
pellet was resuspended with an equal volume of chilled buffer (pH 7.2) containing 130 
mM NaCl, 10 mM NaH2PO4, 10 mM Na2HPO4, 2% NP-40, 1% sodium deoxycholate 
and EDTA-free protease inhibitor cocktail (Roche, Switzerland). After incubation on 
ice for 30 min, the homogenate was subjected to 100,000 g centrifugation at 4
o
C for 
30 min to remove the debris. The supernatant was filtrated with a 0.22 μm filter 
(Millipore, USA) followed by pouring over the ImmunoPure Immobilized Protein A 
column (Pierce, USA) to remove the endogenous immunoglobulins. The filtrated 
solution was incubated with 1 ml of Protein A resin cross-link to mouse-PrP specific 
monoclonal 4H11 antibody at 4
o
C over night. Then the resin was washed with 10 
volumes of washing buffer (20 mM Tris-HCl, 500 mM NaCl and 5 mM EDTA, pH 8.0) 
followed by washing with 10 volumes of 1×PBS containing 0.5% NP-40. PrP
C
 was 
eluted with 5 ml of 200 mM glycine. The solution was loaded into 10 kDa filter 
centrifugal tubes (Millipore, USA) to centrifuge at 3,000 g at 4
o
C for 1 h for desalting 
and buffer exchanging. Then the protein was resuspended with 5 ml of 1×QuIC buffer 
and subjected to gel filtration by passing over the Superdex 75 column (GE lifescience, 
USA). The harvested protein in the peak was concentrated with a 10 kDa filter 
centrifugal tube (Millipore, USA) followed by estimating protein concentration with 
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quantitative immunoblot. The yield of mouse PrP
C
 was approx. 3 μg/brain. 
3.15 Performing qRT-QuIC 
The qRT-QuIC reactions were performed in the volume of 100 μl containing (final 
concentrations after seeding) 400 mM NaCl, 5 mM NaH2PO4, 5 mM Na2HPO4, 1 mM 
EDTA, 100 μM thioflavin T and 100 μg/ml rPrP (pH 7.2) in a Nunc 96-well plate 
(Thermo Scientific, USA). These ingredients were firstly prepared as a master mix 
preparation (90 μl for each reaction) before seeding 10 μl of seeds (purified PrPres 
and PrP
C
). Before reaction, the plate was sealed carefully with transparent tape for
avoiding cross-contamination and aerosol. Reactions were performed on a FLUOstar 
Optima (BMG Labtech, Germany) at 37
o
C for 90 hours with 1 min shaking at 600 rpm
followed by 1 min stationary incubation. The fluorescence was measured with bottom 
optic every hour. The excitation was 440 nm, emission was 480 nm and the gain 
setting was 2000. Curves and intersecting lines (for indicating both the threshold and 
required hour) were directly shown by the provided functions of BMG Optima Data 
Analysis software.  
3.16   PK-digestion and Western blotting for establishing 
qRT-QuIC 
Ten percent (w/v) brain homogenates of RML- and ME7-infected mice and purified 
RML- and ME7-PrPres were digested with 100 μg/ml of proteinase-K (Roche, 
Switzerland) at 37
o
C for 1 h. The digestions were stopped by heating at 100
o
C for 10
min with 2×loading buffer. The proteins were separated in a 15% SDS-PAGE followed 
by transfer to a PVDF membrane (Millipore, USA). The membrane was blocked with 
5% non-fat milk for 1 h at room temperature. The proteins were detected with 
mouse-PrP specific 4H11 monoclonal antibody. Signals were measured on a Diana III 
luminescence imaging system (Raytest, Germany). 
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3.17   Purifying PrPres from urine and brain for monitoring 
anti-prion therapy 
Urine was harvested from anle138b treated mice with Pasteur pipets. Mouse urine of 
200 μl was treated by 1 μg/ml of PK at 37
o
C for 1 h followed by stopping digestion with 
5 mM PMSF (final concentration). The PK-treated urine was transferred into 300 μl of 
1 × QuIC buffer (130 mM NaCl, 5 mM NaH2PO4, 5 mM Na2HPO4 and 1 mM EDTA, pH 
7.4). The total volume reached 500 μl. The followed steps of purifying urinary PrPres 
and the protocol of preparing brain-derived PrPres for qRT-QuIC were the same as 
the description in section 3.13. The normal mouse urine and brain were treated with 
the protocols of purifying PrPres from infected urine and brain. 
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4   Results 
4.1   Screening compounds of inhibiting prion formation 
4.1.1 Discovery of anle138b by screening for anti-prion 
compounds  
Before the start of my dissertation, the research group of Prof. Armin Giese had tested 
a compound collection of 20,000 chemically diverse drug-like compounds both for 
inhibition of prion protein aggregation using both molecular SIFT assay (Bertsch et al, 
2005; Bieschke et al, 2000) and anti-prion cell culture assay (Leidel et al, 2011; 
Geissen et al, 2011). Structure-activity and cluster analysis of the data obtained with 
two assays identified a cluster of highly active compounds belonging to the chemical 
class of 3,5-diphenyl-pyrazole (DPP) derivatives (This part of work was done by Uwe 
Bertsch, Thomas Hirschberger, and Armin Giese, see ref. Wagner et al, 2013). 
Therefore, in collaboration with the group of Christian Griesinger at the Max-Planck 
Institute for biophysical chemistry in Göttingen, a focussed library of ~150 
DPP-related compounds was designed, synthezised and tested in vitro for inhibition 
formation of pathological PrP
Sc
, in cell-culture, and in vivo for therapeutic effects on 
disease progression and oligomer formation in a range of animal models. A detailed 
account of our experimental drug discovery strategy is provided (Figure 8). An 
evaluation of the DPP leader structure according to medicinal chemistry criteria (Clark, 
2003; Lipinski et al, 2001; Veber et al, 2002) indicated good metabolic stability and 
oral bioavailability required for long term therapy. In vivo experiments were done in the 
prion-infected mouse model, as this provides an authentic neurodegenerative disease 
model with a well-defined and relatively rapid time course. Compounds were given 
orally and, in addition to therapeutic efficacy, brain levels were investigated for a 
number of compounds (Table 1).  
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Figure 8. Summary of experimental strategy. In a first project phase, a library of 
10,000 chemically diverse drug-like compounds was tested in regard to inhibition of 
prion protein aggregation in a molecular SIFT screening assay. Based on this data in 
combination with testing of primary hits in a cellular anti-prion assay, 
N-benzylidene-benzohydrazide (NBB) derivatives were identified as a new lead 
structure with anti-prion activity providing a proof of principle of the experimental 
strategy. However, NBB´s contain a Schiff´s base like =N-NH-CO- structure that can 
result in rapid metabolism in vivo. In order to identify further lead structures with 
favorable medicinal chemical properties, the project was continued by screening of 
10,000 additional compounds and a parallel analysis of all these 20,000 compounds 
in a microtiter plate based high-throughput anti-prion cell culture assay followed by 
structure-activity and cluster analysis of the data obtained with these two independent 
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approaches. This analysis identified a cluster of highly active compounds belonging to 
the chemical compound class of 3,5-diphenyl-pyrazole (DPP) derivatives. Thereafter, 
we synthesized a focused library of ~150 DPP-related compounds for further  testing 
in PMCA, in cell-culture, and in vivo in regard to therapeutic effects on prion 
aggregation and disease progression in animal models. Based on results from these 
anti-prion assays, 38 compounds were selected for in vivo testing in prion-infected 
mice. In these experiments, the compound anle138b 
[3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole] showed the highest 
anti-prion activity.  
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Table 1. Structure-activity relationship for various DPP-derivatives. 
The table summarizes the effect of various compounds in regard to prion propagation 
in vitro (SIFT, PMCA) and in vivo in prion-infected mice, as well as compound 
concentrations achieved in the brain 4 hours after oral application of 1 mg compound 
in DMSO/peanut butter. For all compounds other than anle138b, only the part of the 
molecule (R1, R2, or R3) that differs from this lead structure is displayed.  
#  inhibition relative to high control, 10 µM compound, RML prion strain. 
＊ relative inhibition of PrP
Sc 
accumulation normalized to DMSO-treated group (0%
inhibition) and PrP
Sc
 level at start of treatment (100% inhibition).
a  PrP
Sc
 level in brain 120 days after i.c. infection and treatment for 40 days with 1
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mg compound (oral, in peanut butter).  
b  PrP
Sc
 level in spleen determined 35 days after i.p. infection followed by 34 days of
treatment with 1 mg compound (oral, in peanut butter).  
c  PrP
Sc
 level in brain at 106 days after i.c. infection and treatment for 24 days (14
days i.p. (0.84 mg compound); 2 x 5 days oral by gavage (1 mg)). 
anle138b [3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole] showed the 
highest anti-prion activity both in vivo and in vitro (Figure 9). Comparison of anle138b 
with systematic variations of this structure revealed a well-defined structure-activity 
relationship (SAR). Regarding the 5-phenyl (R3), bromine in meta-position led to the 
highest inhibitory activity, whereas the change of bromine location to para- or 
ortho-position in the 5-phenyl ring (R3) reduced or abolished the activity, respectively. 
Interestingly, substitution in the ortho-position for steric reasons tilts this phenyl ring so 
that the molecule is no longer planar (Wagner et al, 2013). Testing different halogen 
atoms in the meta-position revealed a bell-shaped correlation with the size of the 
substituent. Regarding the central five-membered ring (R2), pyrazole was associated 
with the highest activity. For the substituent at the 3-phenyl (R1), SAR was more 
complex, as modifications in this position strongly affected bioavailability in the brain. 
1,3-Benzodioxole as in anle138b was associated with the best bioavailability and 
good inhibitory activity in vitro, thus resulting in the highest activity in vivo. Notably, 
when brain levels are taken into account, there is a strong correlation between 
anti-prion activity in vitro and in vivo (Figure 9), indicating that the therapeutic effect in 
vivo is based on direct targeting of PrP
Sc
.
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Figure 9. Correlation between anti-prion activity in vitro and in vivo. For 
compounds shown in Table 1 that reach brain levels 15 nmol/g (indicated by dark blue 
dots), there is a strong linear correlation (R = 0.951) between anti-prion activity in vitro 
and in vivo. Those compounds that reach lower brain levels (represented as light blue 
dots) result in lower in vivo activities. No compounds with low anti-prion activity in the 
PMCA assay in vitro are active in vivo. Anle138b is the most active compound in both 
assays. Anti-prion activity is provided as % inhibition. 
4.1.2 Efficacy of treatment started after the onset of disease 
SAR was primarily investigated through the effect of treatment for 40 days (80-120 dpi) 
on PrP
Sc
 accumulation, which provides rapid and reliable biochemical quantification
and thus allowed testing of a large number of compounds in vivo. To further 
investigate the mode of action and therapeutic potency, we chose anle138b, which in 
our SAR study had the highest therapeutic efficacy in vivo. To be useful for treatment 
in humans, a compound should also be effective when given after signs and 
symptoms of disease are detectable. Thus, we analysed the effect on clinical outcome 
(i.e. motor performance, weight loss, and survival) for treatment started at different 
time points after intracerebral infection (Figure 10). Without treatment, at about 80 dpi 
subtle clinical signs can be observed (Mallucci et al, 2007) and PrPres is detectable in 
the brain (Figure 10 c), at 120 dpi obvious signs of disease are present (Figure 10 b 
and c). Even start of treatment with anle138b after onset of disease at 120 dpi 
resulted in a substantially prolonged survival and preservation of body weight (Figure 
10 a and b). To our knowledge, the prolongation of survival obtained with anle138b is 
the largest that has been found for any drug-like compound tested so far in late-stage 
treatment experiments (Demaimay et al, 1997; Trevitt and Collinge, 2006; Kawasaki 
et al, 2007; Colombo et al, 2009). The medicinal chemistry optimization of DPP 
compounds thus was essential for high in vivo efficacy compared to the efficacy 
observed for the first hit compounds derived from the compound collection used for 
primary screening (Leidel et al, 2011; Geissen et al, 2011). Analysis of mice at 
different time points during treatment revealed that anle138b strongly inhibited 
accumulation of PrP
Sc
 (Figure 10 c and d) and neuronal cell death (Figure 10 e)
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even when the start of treatment was in the symptomatic phase. Interestingly, the 
number of pyknotic nuclei indicating apoptotic neuronal cell death seemed not to 
depend on the absolute amount of PrP
Sc
 but correlated with the rate of PrP
Sc
amplification. This is in line with published data (Collinge, 2001) and provides an 
explanation for the strong therapeutic effect found also in the late-treatment group.  
Figure 10. Influence of daily anle138b treatment on PrP
Sc
 accumulation and
prion pathology of mice infected with RML scrapie. (a) Survival curves of mice 
treated orally with anle138b beginning at 0, 80 or 120 days post i.c. prion infection. 
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Treatment resulted in prolonged survival, even when started at an advanced disease 
stage at 120 dpi. (b) Control mice showed a progressive weight loss starting after 100 
dpi. Treatment with anle138b from 80 dpi onwards prevents weight loss for ~100 days. 
Treatment from 120 dpi inhibits further weight loss for ~70 days. (c) 
Immunohistochemistry (upper row: cortex/hippocampus, middle row: cerebellum) and 
dot blot analysis (lower row) showed that anle138b treatment inhibits PrP
Sc
 
accumulation in comparison to DMSO-treated control animals. (d) Quantification of 
brain PrP
Sc
 levels at different time points shows highly significant inhibition of PrP
Sc
 
accumulation in mice treated from 80 dpi onwards. PrP
Sc
 accumulation is also 
reduced in animals treated from 120 dpi. (e) Histological analysis reveals a 
significantly reduced number of pyknotic nuclei both in mice treated from 80 dpi and 
120 dpi onwards. Inset is an example of a pyknotic granule cell nucleus (arrow). Error 
bars in (d) and (e) indicate standard error (n = 4), ** = p < 0.01, *** = p < 0.001. The 
legend shown in (a) is also applicable to (b), (d) and (e). 
 
 
4.1.3   Targeting of pathological PrPSc aggregation by anle138b  
Regarding the mode of action, these findings in combination with the finding that PrP
C
 
expression is unaffected by anle138b (Wagner et al, 2013) indicate that anle138b 
directly blocks PrP
Sc 
amplification and reduces neurotoxicity in vivo. Notably, we 
observed a significant change in size distribution of aggregates indicating a 
modulation of the abundance of different oligomeric species. To characterize oligomer 
formation in vivo, we used sucrose gradient centrifugation, as this method, which is 
well established in the prion field (Prusiner et al, 1980), has several advantages 
compared to other methods for analysis of size distribution of aggregates: i) It allows 
direct analysis of brain homogenates, which would be difficult by gel filtration, ii) there 
is no purification step, which might modify the aggregation state before analysis, and 
iii) it allows to detect and quantify all potential particle sizes (i.e. monomers, oligomers, 
fibrils) simultaneously. Analysis of brain homogenates by sucrose-gradient 
centrifugation assay reveals a strong reduction of high molecular weight species and 
also a shift towards smaller oligomer size for low molecular weight oligomers (Figure 
11). That oligomer modulation - in addition to reduced toxicity - also interferes with 
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PrP
Sc
 amplification is further corroborated by the fact that PrP
Sc
 amplification is also 
blocked in PMCA assay (Figure 12). This method provides several key advantages 
for compound testing. It has been shown that PMCA provides an experimental tool for 
rapid propagation of authentic infectious prions in vitro (Weber et al, 2006) and 
preserves strain properties (Castilla et al, 2008). Importantly, this approach constitutes 
the only experimental approach to test the efficacy of compounds in a purely human 
system (human prions + human brain tissue). Moreover, we found that the results 
obtained in the PMCA assay are predictive for the effects observed in vivo (Table 1, 
Figure 10). We tested anle138b using a range of murine (RML, ME7 and 301C (i.e. 
mouse-adapted BSE)) and human strains (sCJD and vCJD). Anle138b strongly 
inhibited all prion strains tested including BSE-derived and human prions in a purely 
human system. Dose-response curves for the RML prion strain used in our animal 
experiments and for human vCJD were similar (EC50 RML = 7.3 µM, EC50 vCJD = 
7.1µM), indicating that this compound may also be useful for treatment of human prion 
disease (Figure 13).  
 
 
 
Figure 11. Size modulation of mouse RML PrP
Sc
/PrPres oligomers by anle138b. 
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(a) Size distribution of PrP
Sc
 aggregates was analyzed by sucrose gradient 
centrifugation, PK-digestion and WB. (b) Quantifications of WBs show that mice 
treated with anle138b show a strong reduction of high molecular weight species 
(fractions 7-12). Also small molecular weight oligomers (fractions 3-4) are reduced 
and show a shift towards smaller size (fraction 2) indicating that anle138b blocks 
aggregation at the level of small oligomers. DMSO-treated mice are indistinguishable 
from terminally ill untreated mice. Shown are mean ± s.e.m. 
 
 
 
Figure 12. Inhibition of various human and non-human prion strains in PMCA. 
For PMCA assay, infected brain homogenates were diluted 100-fold by appropriate 
normal brain homogenates containing compounds (1 μl of 10 mM solutions in DMSO) 
or 1 μl of DMSO as control. (a) Mouse-adapted scrapie strains (RML, ME7) and 
Mouse-adapted BSE (301C) were used as seed in C57BL/6 mouse normal brain 
homogenates. (b) sCJD and vCJD samples were propagated in non-CJD human 
brain homogenates. sCJD MM1, the type 1 sCJD whose PrP is methione/methione 
homozygous at codon 129 aa; sCJD MV2, the type 2 sCJD whose PrP is 
methione/valine heterozygous at codon 129 aa; vCJD is methionine/methionine 
homozygous. Non-CJD human brains prepared for PMCA substrates were selected. 
In all gels, 0.5% (w/v) normal brain homogenates from C57B/L6 and human brain, 
respectively, were loaded directly in the last lane as a reference without proteolysis 
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(indicated as PrP
C
 on the top). All other samples were treated with 50 μg/ml PK. ‘Start’ 
indicates those samples containing infected brain homogenates before PMCA (lane 1 
of each gel). Molecular weight markers are indicated on the right. PrP migrates in 
three different bands due to the presence of unglycosylated, monoglycosylated, and 
diglycosylated forms, and digestion with Proteinase K results in a shift to lower 
molecular weights with the unglycosylated band migrating at ~20 kDa. Anle138b 
shows a strong inhibitory activity in all prion strains tested. As an additional control, 
the inactive isomer anle234b (see Table 1) was used.  
 
 
 
Figure 13. Inhibition of in vitro propagation of different prion strains by 
anle138b.  
(a) Normal brain homogenates of C57BL/6 mouse and human seeded with a 100-fold 
dilution of infected brain homogenates respectively were mixed with different 
concentration of anle138b (0, 1, 3, 10, 30, 100 and 300 μM, final concentration). 
PMCA reactions were conducted 18 cycles for mouse substrate and 40 cycles for 
human substrate. The effect of anle138b was dose-dependent. Molecular weight 
markers are indicated on the right in kDa. (b) The amount of PrP
Sc
 was quantified 
densitometrically and normalized to the control reaction without compound. Similar 
dose-response curves were obtained for human prions (vCJD) and for the murine 
prion strain RML that was used in animal experiments. Three independent 
experiments were carried out. Results are presented as mean ± s.e.m.  
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4.1.4   Therapeutic efficacy of anle138b in Parkinson disease (PD) 
α-Synucleinopathies share molecular features in regard to aggregate structure and 
seeding with prion diseases (Glabe and Kayed, 2006; Angot et al, 2010; Luk et al, 
2012) and are of high clinical importance due to their high prevalence (Forman et al, 
2005). Thus, we tested our library of DPP-derivatives with respect to effects on α-syn 
oligomer formation and surprisingly found that Anle138b turned out to inhibit α-syn 
oligomer formation at the same concentration range that was active in the PMCA 
anti-prion assay and that was reached in brain tissue (the in vitro SIFT assay and in 
vivo survival tests of screening anti-PD compounds were done by Armin Giese, 
Johannes Levin, Felix Schmidt and Catharina Prix, see ref. Wagner et al, 2013). 
Similar to the prion mouse model, we found a strong reduction of pathological α-syn 
oligomers in the anle138b treated mice (Figure 14). The level of total α-syn was 
unchanged in anle138b-treated mice (Wagner et al, 2013), indicating that anle138b 
does not interfere with expression and degradation of α-syn in these mice but acts as 
an aggregation inhibitor.  
 
 
Figure 14. (a) Sucrose gradient centrifugation shows that in young transgenic mice 
α-syn is found in the same fractions (1-2) as monomeric recombinant α-syn. In 
69-weeks-old placebo-treated mice (DMSO), α-syn oligomers can be found that show 
the same size distribution as oligomers derived from recombinant α-syn by treatment 
with DMSO/Fe
3+
. Oligomer formation in transgenic mice is inhibited by treatment with 
anle138b. For the corresponding graph shown in (b), four mice per group were 
analyzed. 
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4.2   Establishment of RT-QuIC for prion diagnosis 
 
4.2.1 Minimum component for prion propagation 
PrP
Sc
 is an abnormal protein thought to be the only essential component of infectious 
prion agents. The ‘protein-only’ hypothesis proposed by S. B. Prusiner (Prusiner, 1998) 
postulates that both the transmission and infection of prions are only caused by this 
protein PrP
Sc
 and without any other participant. According to this hypothesis, PrP
Sc
 
should be the only component that can convert normal PrP
C
 into abnormal forms both 
in vitro and cause prion diseases in vivo. In other words, understanding the conditions 
of prion transmission and propagation depends on investigating the elements on the 
side of host tissues but not the side of prion particles. Thus, a ‘bottom-up’ study can be 
logically raised: spiking PrP
Sc
 into a system that contains as few factors as possible, 
e.g., only PrP
C
, to see if the PrP
Sc
 can still propagate and to test potential cofactors 
derived from normal cells that may enhance the amplification of PrP
Sc
. Theoretically, 
this strategy can help to not only investigate the mechanism of prion propagation, but 
also establish a sensitive amplification system of prion diagnosis that can detect small 
amount of PrP
Sc
 in vitro. 
 
Many studies have addressed this strategy by testing many cellular elements that may 
help the invasion and propagation of prions (Telling et al, 1995; Deleault et al, 2003; 
Deleault et al, 2007; Atarashi et al, 2007; Wang et al, 2010; Kim et al, 2010). With 
more potential cofactors to be found, the available evidence indicates a simple truth: 
prion propagation in affected individuals is rather complex involving many cellular 
components so that the mechanism of prion propagation has not been settled yet. 
However, attempts of developing diagnostic techniques for prion diseases have made 
an achievement that allows efficient prion amplification in a minimal system that 
contains just bacterially expressed recombinant prion protein (rPrP) substrate and 
spiked prion seeds without any association with other mammalian cellular cofactors. 
This technique is termed quaking-induced conversion (QuIC) (Figure 15) (Atarashi et 
al, 2008). 
Results 
 
 
 
43 
 
 
Figure 15. Detecting PrP
Sc
 of human in QuIC reaction. The classical technique for 
detecting human PrP
Sc
 is to digest the brain homogenates with PK followed by 
detecting PrPres with WBs (upper panels). This technique is limited by the 
sensitivities of WB, e.g., PrPres signals of vCJD and sCJD are undetectable in 
≥10
-2.5
-diluted brain homogenates. Thus, WB can detect PrPres only in the brains of 
biopsy or autopsy harvested from the CJD patients of terminal stage. WB cannot fulfill 
the requirement of early stage diagnosis that is needed to facilitate early (i.e. 
presymptomatic) anti-prion treatment. QuIC is a prion propagation system that mixing 
PrP
Sc
 and rPrP substrate to amplify PrP
Sc
 in vitro. PK-digested QuIC products can be 
analyzed by WB to detect newly formed rPrPres (lower panel). Reactions seeded by 
diluted CJD brains (10
-3
 to 10
-6
-fold dilution), but not that seeded by diluted non-CJD 
brain, show positive rPrPres bands in WB, indicated that small amounts of PrP
Sc
 
which cannot be detected directly by normal WB are amplified to reach the detectable 
levels by QuIC. Human brain-derived PrP contains 3 glycosylated forms: 
diglycosylated, monoglycosylated and unglycosylated. Thus, human PrPres shows 3 
separated bands in normal WB. In contrast, both bacterially expressed rPrP substrate 
and PK-digested rPrPres has only one band that lacks glycosylation.. 
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4.2.2 Technique evolution from QuIC to RT-QuIC 
By automatically converting rPrP substrate into partially PK-resistant rPrP (rPrPres), 
PrP
Sc
 in seeded sample can be amplified in the QuIC system. Although QuIC has 
shown its ability of detecting rather small amount of PrP
Sc
 through ‘prion propagation’, 
the time-span of reaction and the consecutive PK-digestion and Western blotting 
steps are problematic for a routine diagnostic application. For example, QuIC is still an 
end-point diagnostic technique so that the reaction must be stopped at a very right 
time when PrP
Sc
 has been amplified but those ‘neat’ reactions have not caused 
spontaneous conversion of rPrP to rPrPres yet. Therefore, QuIC technique has to be 
optimized by employing rPrP substrates of many species and multiple working 
conditions including temperature, detergent and ion strength (Atarashi et al, 2008). 
Furthermore, results of tests will not be available before digesting the products with 
PK of right concentrations and detecting with antibody of right types (monoclonal or 
polyclonal against the epitopes on PK-resistant pattern of rPrPres) (Atarashi et al, 
2007; Atarashi et al, 2008).  
 
A study termed amyloid seeding assay (ASA) showed that the newly formed rPrPres 
can be detected by fluorescence caused by thioflavin T (ThT)-binding to the β-sheet of 
rPrPres (Colby et al, 2007). Despite the fact that neither the sensitivity nor specificity 
of ASA is ideal, it at least suggests a method of using ThT as the detection agent in a 
well-defined system of prion amplification. Hence, a technique termed real-time QuIC 
(RT-QuIC) has been developed (Wilham et al, 2010). By adding ThT into the QuIC 
assay system followed by performing prion amplification in an automated 
fluorescence reader, the conversion of PrP
Sc
 can be observed directly. Thus, a much 
easier detection can be achieved. RT-QuIC overcomes the shortages of QuIC 
discussed above and, allows performing multiple reactions at the same time, e.g., in a 
96-well or 384-well plate. This is very important because it fulfills the requirement of 
detecting prions in a high-throughput system.  
 
Based on the both sensitivity and specificity shown in experimental studies, RT-QuIC 
has been subjected to clinical trials of diagnosis of human prion diseases. Current 
seeds for human trials are cerebrospinal fluid (CSF) samples obtained from definite 
CJD (for positive controls and pilot studies) and probable CJD (for case-control and 
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cohort studies) patients, since both the existence and low infectivity of prion in CSF 
has been addressed (Brown et al, 1994). A recent study showed 80% sensitivity and 
100% specificity of using RT-QuIC to diagnose CJD in CSF (Atarashi et al, 2011), 
while another study showed these two quotas with 91% and 98% (McGuire et al, 
2012), respectively. Both studies showed better sensitivity and specificity, respectively, 
than detecting 14-3-3 protein, another protein marker widely accepted for diagnosing 
suspected sCJD in human CSF (Collins et al, 2000; Sanchez-Juan et al, 2006). 
 
4.2.3   Establishment of RT-QuIC for diagnosing human CJD in 
CSF 
The pilot study of RT-QuIC tests was separated in two parts: i) test the sensitivity and 
specificity of RT-QuIC of detecting PrP
Sc
 in diluted human brains and CSF, and ii) test 
blindly prepared CSF samples of our own collection. As described before, RT-QuIC 
results of prion amplification can be indicated directly by the ascendant curves of 
ThT-fluorescence (Figure 16). RT-QuIC showed high reliability when detecting PrP
Sc
 
in diluted human brains and CSF by using human rPrP substrate in reactions (Figure 
17). I obtained 100% sensitivity and 100% specificity for detecting known CJD 
samples (Table 2). Thereafter, human CSF samples of our own collections were 
prepared blindly in two batches followed by seeding into RT-QuIC. Again, I obtained 
100% reliability of discriminating CJD and non-CJD CSF samples in RT-QuIC (Table 
3). These results indicate that the RT-QuIC technique in our lab has been established 
to detect prions. 
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Figure 16. One typical read-out of RT-QuIC of amplifying PrP
Sc
 with a 96-well 
plate. rPrP substrate was spiked with PrP
Sc
 samples or non-prion brain control 
followed by performing in RT-QuIC reactions for several hours (normally 90-96 h). 
Those rPrP substrates seeded by samples containing PrP
Sc
 were converted into 
β-sheet rich rPrPres which was detected by ThT fluorescence and show ascendant 
curves in real-time. In this plate, each sample was repeated with triplicate (i.e., wells 
A1-A3 were seeded by the PrP
Sc
 sample coming from one preparation of prion 
disease, wells B1-B3 were seeded by the control sample coming from one non-prion 
preparation, etc.). Parallel repeats in RT-QuIC are essential because in some cases, 
the pipetting error causes unstable amplification for detecting PrP
Sc
 (e.g., F1-F3 and 
H1-H3, which wells were all seeded with PrP
Sc
 samples), or even false-negativity (e.g., 
F10-F12). ‘blanks’ indicated in the bottom row are solutions containing PrP
Sc
 but not 
rPrP substrate for showing that ascendant curves are caused by the growth of rPrPres 
but not seeds. 
 
 
 
Figure 17. Discriminating human sCJD from Alzheimer disease (AD) by 
amplifying PrP
Sc
 of CSF with RT-QuIC. CSF samples of definite sCJD and AD were 
spiked 10 μl into RT-QuIC reactions containing human rPrP substrate. These 
reactions were performed for 120 h and the positive reactions were indicated by 
ascendant curves in read-outs. Human sCJD cases are MM1 (methionine/methionine 
homozygous type 1), MV2 (methionine/valine heterozygous type 2) and VV2 
(valine/valine homozygous type 2). AD CSF samples were chosen corresponding 
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genotypes (represented as MM, MV and VV, respectively). Each type of CJD and AD 
has 2 randomly selected cases (indicated as 1 and 2). All CJD cases are positive at 
~8 h, and none of AD case shows false-positivity in 120 h, indicating high reliability of 
RT-QuIC amplification system for detecting PrP
Sc
 in human CSF. This result is a 
combination of zoom-in data coming from several wells of a plate like those shown in 
Figure 16. 
 
 
Table 2. Summary of one batch of pilot study 
 
CSF Replication positive negative sensitivity specificity 
CJD  64 256 64 (256) 0  100% - 
Non-CJD  78 312 0  78 (312) - 100% 
In this batch of pilot study, CSF samples of 64 definite CJD cases and 78 non-CJD 
cases were tested. RT-QuIC of each case was prepared in 4 parallel reactions. Every 
RT-QuIC reaction seeded by CJD CSF showed positive (100% sensitivity), and every 
non-CJD CSF showed negative (100% specificity). Pilot study was done in several 
batches to test the reliability and reproducibility of using RT-QuIC for the detection of 
human PrP
Sc
. 
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Table 3. Summary of one batch of blind test (BT) by using CSF samples of own 
collection 
 
Subject key: sCJD, sporadic Creutzfeldt-Jakob disease; AD, Alzheimer disease; PD, 
Parkinson disease; inflammation, normal inflammation in the brain without 
neurodegenerative change. Shown ‘RT-QuIC’ columns are results indicated with 
numbers of positive reaction/performed reaction.  
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4.2.4   Diagnosing human CJD in CSF samples obtained by 
international collaborations 
To test the utility of RT-QuIC in our lab for diagnosing human CJD patients by 
detecting PrP
Sc
 in the CSF, I received two batches of blinded human CSF samples 
from NCJDRSU (The National CJD Research & Surveillance Unit, University of 
Edinburgh, UK). After gaining the results, I sent the diagnostic conclusions back to 
NCJDRSU for judgment. As expected, I observed 100% of both sensitivity and 
specificity. It is noteworthy that most of these blinded samples are from patients who 
are still living in the hospital. These results of blinded tests indicate that RT-QuIC is a 
reliable technique for prion diagnosis is feasible in our lab.  
 
Since I found that the patented human rPrP (Song Shi, Armin Giese and Hans 
Kretzschmar, Method for the isolation of recombinant prion protein and the use thereof, 
EP 13182421.1) seemed to be a better substrate for amplifying human CJD in 
RT-QuIC reactions, I compared this rPrP substrate with hamster rPrP prepared by 
NCJDRSU and NIH (McGuire et al, 2012; Peden et al, 2012; Wilham et al, 2010). I 
found that RT-QuIC reactions containing human rPrP gave much shorter lag-phases 
of amplification than hamster rPrP. More importantly, reactions using human rPrP had 
better reproducibility than those using hamster rPrP. Furthermore, much higher 
relative fluorescence unit (RFU) that facilitated to immediately distinguish CJD CSF 
from those non-CJD cases was observed in reactions containing human rPrP but not 
hamster rPrP. These results suggest that it may be necessary to prepare rPrP of 
different species for detecting various prion strains. Details are provided for blinded 
testing of samples from international collaboration (Figure 18, 19, 20, 21 and Table 4, 
5). 
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Figure 18. Reactions using hamster rPrP (NCJDRSU) and human rPrP (ZNP) 
substrates are seeded with blinded CSF samples from the UK for testing the 
reliability of RT-QuIC. Each sample was done with triplication. Results showed that 
reactions using hamster rPrP produce comparable conclusions with those using 
human rPrP. However, fluorescence of hamster rPrPres is much lower than that of 
human rPrPres. For testing of hamster rPrP, each well was seeded with 15 μl of CSF 
into 85 μl of substrate preparation containing 100 μg/ml rPrP (final concentration). For 
testing of human rPrP, each well was seeded with 10 μl of CSF into 90 μl of substrate 
preparation containing 100 μg/ml rPrP (final concentration). The results are 
summarized in Table 4. 
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Table 4. Summary of the first batch of collaborated blind test for diagnosing 
CJD in CSF 
 
These results were confirmed at the NCJDRSU with 100% sensitivity and 100% 
specificity. 
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Figure 19. Testing reliability of RT-QuIC using NCJDRSU supplied hamster rPrP 
substrate and human CSF for diagnosis of CJD (second round). Each sample 
was tested in triplicate and RT-QuIC was performed twice independently (plate 1 and 
2). Results of two runs are not fully comparable with each other, e.g., A2 is positive in 
plate 1 bur negative in plate 2, A7 and A8 are negative in plate 1 but positive in plate 2. 
Each well was seeded with 30 μl of CSF into 70 μl of substrate preparation containing 
100 μg/ml hamster rPrP (final concentration). Summary is shown in Table 5. 
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Figure 20. Testing reliability of RT-QuIC using self-prepared human rPrP 
substrate and human CSF for diagnosis of CJD (second round). Each sample 
was tested in triplicate and RT-QuIC was performed twice independently (plate 1 and 
2). Constantly, fluorescence provided by human rPrPres shows higher performance 
than that of hamster rPrPres shown in Figure 19, indicating that more β-sheet rich 
rPrPres is formed in these reactions. It is noteworthy that results of this figure are from 
72 h while those in Figure 19 are from 120 h, suggesting that human rPrP substrate is 
more sensitive to detect human PrP
Sc
 in RT-QuIC. Each well was seeded with 10 μl of 
CSF into 90 μl of substrate preparation containing 100 μg/ml human rPrP (final 
concentration). Comparison of profiles is shown in Figure 19. Summary is shown in 
table 5. 
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Figure 21. Zoom-in profiles of RT-QuIC result of directly comparing the 
performance of hamster rPrP substrate to human rPrP. C3 and C4 wells seeded 
with identical cases (1445 and 1496) in each plate shown in Figure 19 and 20 were 
chosen. Positive reactions using hamster rPrP show lag-phases from 30 to 40 h and 
fluorescence intensities (RFU) from 20 000 to 40 000 which are caused by 
amplification of PrP
Sc
 in 30 μl of human CJD CSF. Reactions using human rPrP 
provide < 24 h of lag-phases and 50 000 to above 60 000 RFU which are caused by 
only 10 μl of human CJD CSF. Due to the high performance of human rPrP substrate, 
we concluded that it is not essential to run these reactions longer than 72 h. 
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Table 5. Summary of the second batch of collaborated blind test (NCJDRSU 
confirmed results) 
 
For those using hamster rPrP from NCJDRSU (red labeled). 
 case 1180 (A1-A3), positive in test 1, negative in test 2, diagnose as probable 
CJD;  
 case 1215 (A7-A9), negative in test 1, positive in test 2, diagnose as probable 
CJD; 
 case 4407 (F4-F6), positive in test 1, negative in test 2, diagnose as probable 
CJD; 
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For those using ZNP human rPrP (blue labeled). 
 cases above are all positive in test 1 and 2, diagnose as definite CJD. 
 
 
4.2.5   Determining optimal substrates for detection of various 
prions  
I tested for the suitable recombinant prion protein substrates of RT-QuIC to diagnose 
prion diseases of different types and species. The wild-type full-length recombinant 
prion proteins of human, hamster, mouse and sheep were purified. These proteins as 
the substrates were subjected to RT-QuIC reactions seeded by brain samples (10
-8
 g) 
of human sCJD (MM1), human vCJD, cattle classic BSE (C-BSE) and cattle low-type 
BSE (L-BSE), respectively. These reactions were performed at 37
o
C, 42
o
C, 50
o
C and 
55
o
C, respectively (Figure 22).  
 
 
 
Figure 22. RT-QuIC reactions perform at 37
o
C, 42
o
C, 50
o
C and 55
o
C by using 
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human, hamster, mouse and sheep rPrP, respectively. These reactions were 
spiked with 10
-8
 g brain of sCJD (MM1), vCJD, C-BSE and L-BSE for 96 hr of 
amplification, respectively. 10
-8
 g brain of either non-CJD human or normal cattle was 
seeded as the negative control. Positive reactions seeded by prion samples result in 
ascendant curves in RT-QuIC. Neither control seed nor non-rPrP reaction caused 
false-positive result. Shown are average curve of RT-QuIC curves (n = 6 for each 
prion type). 
 
 
I found that human rPrP was suitable to detect all types of prions above at 42
o
C, 50
o
C 
and 55
o
C with the shortest lag-phases comparing to those reactions using 
recombinant protein substrates derived from other species. It seemed that reactions 
seeded with vCJD were not efficient at 37
o
C. Hamster recombinant prion protein 
reacted with sCJD and L-BSE seeds, but did not respond to either vCJD or C-BSE. All 
prion seeds triggered amplifications in the reactions containing mouse recombinant 
prion protein that has comparable activity with recombinant human prion protein in 
RT-QuIC. Recombinant sheep prion protein reacted with prion seeds only at 55
o
C 
showing low curves, suggesting the insufficient activity of sheep rPrP for RT-QuIC 
substrate. These results indicate that protein substrates from different species have 
distinguishable activities of amplifying prions in RT-QuIC. Recombinant prion proteins 
of human and mouse are converted with higher efficacy than those of the hamster and 
sheep.  
 
I also tested the activities of recombinant prion proteins derived from 4 species listed 
above for amplifying relatively low amount of prion (10
-10
 g of brain) from 3 types of 
human sCJD (MM1, MV2 and VV2, Figure 23) at different temperatures in RT-QuIC. 
Human recombinant prion protein showed the highest activity at all temperature 
conditions compared to other species. Human and hamster proteins showed 
comparable activities of amplifying all types of sCJD prions at 42
o
C. Mouse 
recombinant prion protein produced lower curves than those from human and hamster. 
Sheep protein did not detect low amounts of human sCJD prions. These data indicate 
that substrates of both human and hamster are suitable for detecting low amounts of 
sCJD prions, particularly at 42
o
C. Taking the results of Figure 22 and 23 together, I 
therefore conclude that recombinant prion proteins of human and hamster are suitable 
Results 
 
 
58 
to detect human sCJD prions, human and mouse proteins are better to detect human 
vCJD and cattle BSE, and sheep protein is not suitable to detect human and cattle 
prions by RT-QuIC. 
 
 
Figure 23. Detections of CJD prions in the brains (10
-10
 g of brain) of human 
sCJD MM1, MV2 and VV2 by using recombinant prion protein substrates of 
human, mouse, hamster and sheep, respectively. Reactions were performed at 
37
o
C, 42
o
C, 50
o
C and 55
o
C, respectively. 10
-10
 g brain of genotype-correlated (MM, 
MV and VV) non-CJD human cases was applied as negative controls in RT-QuIC. 
Neither control seed nor non-rPrP reaction caused false-positive result. Shown are 
average curve of RT-QuIC (n = 6 for each CJD type). 
 
 
 
Results 
 
 
 
59 
4.3 Establishing qRT-QuIC for quantification of PrPSc in 
prion-infected tissues 
 
4.3.1 Establishing quantitative RT-QuIC 
The mechanism of normal RT-QuIC is based upon the conversion of PK-sensitive 
rPrP into rPrPres conformer, which is rich in -sheet structures, by seeding the 
reaction mixture with PrP
Sc
 and periodic shaking. The correlation between Thioflavin T 
(ThT) fluorescence and seeded amount of rPrPres has been shown in Figure 24 and 
section 2.2.4. These findings drove me to establish a technique termed quantitative 
RT-QuIC (qRT-QuIC). 
 
 
 
Figure 24 The basis of amplifying PrP
Sc
 with RT-QuIC. (a) Schematic illustration of 
RT-QuIC. PrP
Sc
 converts rPrPsen to rPrPres thereby increasing the total amount of 
β-sheeted PrP. This increase can be demonstrated by the increased ThT-fluorescence. 
Therefore, the sample containing PrP
Sc
 (prion) is distinguished from that without PrP
Sc
 
(non-prion). RFU, relative fluorescence units. (b) However, it was not the amount of 
newly formed rPrPres but the lag-time untill the steep increase of amplification 
(ascendant curves) that was related to the seeded quantity of PK-treated PrP
Sc
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(PrPres). Different amounts of purified mouse RML scrapie-prion PrPres and normal 
mouse PrP
C
 were seeded into reactions to perform 80 hours of RT-QuIC. PrP
C
 did not 
cause ascendant curves.  
 
 
To establish a high-throughput quantification system, PrPres derived from two 
mouse-adapted scrapie prion strains, RML and ME7, was purified from infected 
C57BL/6 mouse brains by repeated NaCl precipitation, allowing recovery of 97% of 
the total PrP
Sc 
(Polymenidou et al, 2002). The concentration of PrPres was measured 
by semi-quantitative Western blotting by comparing band intensities of PrPres to 
reference samples containing known quantities of rPrP (Saá et al, 2006). To estimate 
the minimum amount of PrPres equivalent that can start the seeding reaction, I 
serially diluted PrPres (from 10
-8
 to 10
-11.5
 g) (Figure 25 a). 10
-9.5
 g of both RML and 
ME7 PrPres were visible as a faint band on the WB while 10
-10
 g was not detectable. 
As the control, PrP
C
 from healthy C57BL/6 mouse brain was purified and quantified as 
above. For controlling the quality of the real-time curve, the ThT-binding fluorescence 
of both PrPres and PrP
C
 was measured (Figure 25 b); the results showed that the 
fluorescence starting from 10
-9.5
 g of PrPres was identical to that of PrP
C
 and the blank 
(no PrP). Since 10
-10
 g of PrPres from both prion strains was undetectable in either 
WB or ThT-fluorescence, we chose it as the initial seed.  
 
 
Figure 25. Directly detecting purified PrPres with WBs and ThT-binding 
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fluorescence. (a) Purified mouse RML and ME7 scrapie-prion PrPres was serially 
diluted and detected by immunoblotting. Aliquots were digested with 100 μg/ml 
Proteinase K (PK) before loading on the gel. Undigested PrP
C
 is shown as a migration 
control. Signals were detected by 4H11 monoclonal antibody. Molecular weights are 
shown on the right. (b) Fluorescence of purified RML and ME7 PrPres and normal 
PrP
C
 was measured after ThT-binding. The mean and s.e.m. are shown (n=5).  
 
 
To establish the quantitative RT-QuIC (qRT-QuIC), the seeds containing 10
-10
 to 10
-16
 g 
of purified RML and ME7 PrPres and PrP
C
 per 10 μl were prepared by serial half-log 
(10
0.5
-fold) dilution (a total of 39 samples). Full-length mouse rPrPsen (amino acids 
23-230) was utilized as the substrate. To see if preceding PK-digestion affects the 
seeding activity of prion seeds in the qRT-QuIC reaction, preparations using full-length 
mouse rPrP (aa 23-231) as substrate were seeded with 1 ng and 0.1 ng of undigested 
RML-infected brains, and PrPres purified from 1 ng and 0.1 ng of PK-digested brains, 
followed by qRT-QuIC reactions at 37
o
C for 70 hours (Figure 26 a). The results 
showed practically no differences. In order to maintain comparability of results between 
qRT-QuIC and immunoblotting, we chose PK-digested PrPres as the seed in the 
experiments presented here if not indicated otherwise. To define the appropriate 
time-span of qRT-QuIC for obtaining reliable results, non-seeded and 10
-11
 g of PrPres 
seeded qRT-QuIC reactions were performed for 140 hours (Figure 26 b). This result 
showed that non-seeded reactions generated spontaneous conversion after 90 hours; 
this limited the time-span to 90 hours in our study. 
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Figure 26. Determing the seeding activity of PrPres and time span of qRT-QuIC. 
(a) Comparing the seeding activity of PK-digested and undigested prion-infected brains. 
Seeds for RT-QuIC were 1 ng and 0.1 ng of original RML brains of terminally ill 
C57BL/6 mice, or PK-digested PrPres purified from both samples, respectively. 
PK-digestions were performed at 37
o
C for 1 h with 20 μg/ml PK followed by sodium 
chloride precipitation and purification. Reactions seeded by PK-digested and 
undigested 1 ng of normal C57BL/6 mouse brain were set as controls. (b) RT-QuIC 
reactions with seed (10
-11
 g of PrPres) and without seed (non-seeded) were performed 
for 140 hours. The spontaneous conversion of non-seeded reactions is indicated by an 
arrow. Reactions without seed and substrate (blank) were the control. All profiles 
represent the means of three parallel reactions. RFU, relative fluorescence unit. 
 
 
For standardizing the results, a ‘positive reaction’ of RT-QuIC was recorded when the 
detected intensity of fluorescence was equal or higher than a threshold. The threshold 
was 3 times the fluorescence of the initial phase (0 h). The corresponding hours 
required to reach the threshold (Rht) was recorded as the independent variable (x), 
and the equivalent amount of seeded PrPres was the dependent variable (y), as 
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shown in Figure 27 a. Next, RT-QuIC reactions seeded with 10
-10
 to 10
-16
 g of PrPres 
and PrP
C 
were performed up to 90 h (Figure 27 b). Five repeats of RT-QuIC for each 
seeded amount of PrPres and PrP
C
 equivalents (a total of 260 reactions) were tested. 
Reactions seeded with 10
-10
 to 10
-15.5
 g of PrPres were positive within 90 h whereas 
most of those seeded with 10
-16
 g PrPres were negative. Reactions seeded with 
different amounts of PrP
C
 did not show spontaneous conversion up to 90 h. Therefore, 
the RT-QuIC allowed detecting 10
-15.5
 g (≈ 0.32 fg) of PrPres,
 
which was 1 million 
times more sensitive than the WB shown in Figure 25 a. By analyzing the distribution 
of the required hours mathematically using a standard tool (Microsoft Excel), we 
obtained calibration curves and derived two formulas for calculating the quantities of 
seeded RML and ME7 PrPres in the qRT-QuIC system
 
(Figure 27 c). Details of 
running dose-response reactions to obtain those Rhts are shown in Figure 28, 29 and 
30. 
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Figure 27. Establishing the quantitative RT-QuIC (qRT-QuIC). (a) Schematic 
illustration of qRT-QuIC. The PrPres propagating duration (hour) required to reach the 
threshold (Rht) which was at least 3 times the starting fluorescence was set as the 
independent variable (x), the correlated seeded amount of PrPres was the dependent 
variable (y). (b) Different amounts of purified PrPres (10
-10
 to 10
-16
 g with serial 
10
0.5
-fold dilution) were seeded into RT-QuIC reactions using mouse rPrP as the 
substrate. RT-QuIC process was followed from 0 to 90 h by showing the number of 
hours required to reach the threshold (indicated by black arrows and intersecting 
lines). Purified PrP
C
 with identical amounts was seeded in independent RT-QuIC 
reactions as control. Seeded amounts of both PrPres and PrP
C
 are indicated on the 
top right. (c) The results from five repeats of RT-QuIC seeded by PrPres were 
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provided to yield standard calibration curves and formulas for quantification. This 
relates QuIC time necessary to reach the threshold to the amount of seeded PrPres. 
The mean and s.e.m. are shown (n=5). 
 
 
 
Figure 28. Detecting seeded RML PrPres with RT-QuIC. Purified RML PrPres and 
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control PrP
C
 with the quantities from 10
-10
 to 10
-16
 g were seeded into reactions 
independently to perform 90 h of RT-QuIC at 37
o
C. 
 
 
 
Figure 29. Detecting seeded ME7 PrPres with RT-QuIC. Purified ME7 PrPres and 
control PrP
C
 with the quantities from 10
-10
 to 10
-16
 g were seeded into reactions 
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independently to perform 90 h of RT-QuIC at 37
o
C. 
 
 
 
Figure 30. Positive RT-QuIC reactions seeded with PrPres (10
-10
 to 10
-15.5
 g for 
RML and 10
-10
 to 10
-16
 g for ME7) within 90 h are shown. Each scale on the Y-axis 
represents one effective reaction, the X-axis indicates the required hours 
corresponding to the reaction. The reactions seeded with 10
-16
 g of RML PrPres
 
were 
negative up to 90 h and thus are not shown in the figure.  
 
 
4.3.2   Quantification of PrPres in peripheral organs  
To investigate the feasibility of qRT-QuIC to determine the progression of prion 
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disease, qRT-QuIC was used to measure PrPres at different days post inoculation 
(dpi). 30, 60, 90, 120, 135, 150 and 170 dpi were chosen for RML, 30 to 150 dpi were 
chosen for ME7, since 170 dpi denotes the terminal stage of the RML strain while 150 
dpi is the terminal stage of the ME7 strain. Groups of each 5 C57BL/6 mice were 
inoculated intracerebrally and the brains and peripheral tissues (heart, liver, spleen, 
lung, kidney and hind-limb muscle) were harvested at the dpi indicated above. The 
tissues of age-related healthy C57BL/6 mice were chosen as controls (n = 5 for each 
dpi). 10 mg of each tissue were treated with the method of purifying PrPres for 
obtaining tissue extracts as the seeds of RT-QuIC reactions. This purification step was 
important to remove potential components affecting RT-QuIC efficiency. Since the 
PrPres level is much higher in the brain than in other organs, 1 mg of brain from 
infected mice of different time-points was first analyzed by Western blotting for 
obtaining an overview of the presence of PrPres (Figure 31 a). By Western blotting, 
neither in RML nor in ME7 was PrPres detectable at 30 and 60 dpi, in both strains 
PrPres first appeared at 90 dpi and showed a steady increase to the terminal stage. 
For the preparation of RT-QuIC seeds, the brain extracts of 90 to 170 dpi of the brain 
were diluted 10
4
-fold, and those of the spleen and muscle were diluted 10-fold. Before 
measuring PrPres concentrations in peripheral organs, a comparison was done to 
estimate the reliability of qRT-QuIC (Figure 31 b). The results showed that PrPres 
concentrations in the brains obtained from qRT-QuIC were comparable to those from 
quantitative Western blottings at different time points after inoculation (Table 6), 
indicating that qRT-QuIC is suited to measure the PrPres concentrations. 
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Figure 31 Quantification of RML and ME7 PrPres
 
in brain at various days post 
infection (dpi). (a) 1 mg of brain from scrapie-infected mice at was analyzed by WBs 
after digestion with 100 μg/ml PK. PrP
C
 is shown as a migration control. Signals were 
detected by 4H11 monoclonal antibody. Mr is shown on the right. (b) Comparing 
PrPres concentrations measured by quantitative RT-QuIC and qIB (quantitative 
Western blot). The brains of RML-inoculated mice 90 dpi to 170 dpi and 
ME7-inoculated mice 90 to 150 dpi were chosen regarding the capacity of 
immunobloting to detect PrPres from the time-point not earlier than 90 dpi. After 
comparing the quantitations obtained by qRT-QuIC and qIB, the significance (p value) 
was calculated with two-way ANOVA by using detecting methods and time-points as 
the variables. Shown data are mean and s.e.m (n = 5). 
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Table 1. Comparing PrPres concentrations measured by quantitative RT-QuIC 
and quantitative Western blot. 
 
 
 
After 90 h of amplification I calculated the concentration of PrPres equivalents based 
on the detected seeding activity by using the formulas in Figure 27 c. The levels of 
PrPres equivalents (i.e. seeding activity) in the brain showed the expected increasing 
tendency (Figure 32). In particular, seeding activity reached the highest levels at 170 
dpi in the RML strain and 150 dpi in the ME7 strain. The detection of seeding activity 
from 30 to 90 dpi of both prion strains was negative in the heart and hind-limb muscle, 
but the signals from the heart started to show at 135 dpi in the RML strain and 120 dpi 
in the ME7 strain, while those from muscle were positive starting at 120 dpi of the RML 
strain and 90 dpi of ME7. Interestingly, seeding activity in the liver and kidney in the 
RML strain was detectable in early stages (30 and 60 dpi), and disappeared during the 
intermediate stages of infection (90, 120 and 135 dpi), whereas those of 
ME7-infection were continuously negative utill 135 dpi. Seeding activity in the spleen 
of both prion strains was decreasing at early stages followed by an increase in the 
intermediate stages. The concentration of PrPres equivalents in all three tissues was 
increased at late to final stages. No seeding activity was detected in the lungs at any 
time. Since qRT-QuIC was 1 million times more sensitive than normal WB, these 
results suggest a possibility of using qRT-QuIC to track disease progression or 
analyze prion propagation in various tissues. 
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Figure 32. Seeding activity (expressed as PrPres equvalents in g/g tissue) in various 
tissues from different time-points after inoculation was measured by qRT-QuIC by 
using the formulas shown in Figure 27 c. The PrPres concentration corresponding to 
1 LD50 units per gram of tissue is represented by a gray broken line. Shown are the 
mean and s.e.m. (n=5).  
 
 
To demonstrate the feasibility of qRT-QuIC in the assessment of bio-hazard risks, the 
concentration of PrPres/g tissue (g/g) in various tissues measured by qRT-QuIC was 
compared to the reported half-lethal doses (LD50) of both prion strains. The known 
LD50 of RML and ME7 are 10
-8.8
 and 10
-8.3
 g of terminal brains, respectively (Browning 
et al, 2011). Using the PrPres concentration measured by qRT-QuIC, we can roughly 
extrapolate that 1 LD50 unit contained 10
-12.93
 g of PrPres for RML and 10
-12.72
 g for 
ME7. One LD50 unit is shown as the gray dotted lines in Figure 32 to indicate the 
extent of prion concentration in each gram of tissue (Table 7 and 8), suggesting that 
qRT-QuIC can be used for estimating prion contamination in biological materials. As 
our protocol uses an extraction method for PrPres prior to qRT-QuIC that removes 
potentially interfering factors present in peripheral tissues, the calibration curve 
obtained for brain-derived PrPres should also provide meaningful results for other 
tissues from the same species. Moreover, our findings for RML and ME7 indicate that 
similar assay conditions can be efficient for different strains. However, to ensure 
optimum sensitivity, the exact conditions of the qRT-QuIC assay need to be 
established for different species and strains. 
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Table 7. The concentration of PrPres in 7 tissues from RML scrapie-infected 
mice of 7 time-points  
 
Neg indicates the RT-QuIC reaction is negative up to 90 hours. The mean and s.e.m 
are shown. Concentration of PrPres lower than one LD50 unit per gram of brain (1.16 
×10
-13
 g/g brain) is indicated by sparkle 
 
 
Table 8. The concentration of PrPres in 7 tissues from ME7 scrapie-infected 
mice of 6 time-points 
 
Neg indicates the RT-QuIC reaction is negative up to 90 hours. The mean and s.e.m 
are shown. Concentration of PrPres lower than one LD50 unit per gram of brain (1.89 
×10
-13
 g/g brain) is indicated by sparkle. 
 
 
Results 
 
 
 
73 
4.4   Monitoring anti-prion treatment by quantifying PrPSc in the 
urine 
As described in the Introduction, an effective anti-prion compound anle138b has been 
developed for treating prion disease. The common strategy of monitoring PrPres levels 
in the brains harvested at different time-points of prion incubation period to estimate 
disease progress and therapeutic efficacy is acceptable for experiments in rodents, but 
it is not applicable for further clinical tests in humans. For human trials, a safer 
technique is needed that detects PrPres in samples easily obtained, e.g., urine, to 
evaluate the treatment. Since the sensitive and specific qRT-QuIC had been 
established, I chose qRT-QuIC to track progress of prion disease in anle138b-treated 
mice by quantifying PrPres in the urine. 
 
4.4.1   Testing the reliability of quantifying PrPres with qRT-QuIC 
To address the reliability of quantification, the standard quantities of RML PrPres 
purified from 2 mg of infected brains of anle138b-treated and untreated mice of 
different dpi (80, 120 and 170 dpi, and 250 dpi of treated mice) were separated and 
detected by Western blottings (Figure 33a). 80 dpi was chosen since the PrPres in the 
brain at this stage was visible in both immunohistochmistry and WB (Wagner et al, 
2013). 170 dpi was the terminal stage of untreated mice and 250 dpi was that of treated 
ones. Quantities of PrPres were calculated by comparing the signal intensities with 
those of a known amount of rPrP. Results were analyzed statistically to assess 
deceleration of prion propagation in brains after drug treatment (Figure 33b). 
Concentrations of PrPres in untreated mouse brains increased rapidly to reach high 
levels at the terminal stage of RML-infection (170 dpi), which was significantly different 
from the slight increases in treated mice brains (p = 0.006). The treated mice reached a 
terminal stage at 250 dpi presumably due to the accumulative neuronal toxicity of 
prions although the PrP
Sc
 level was lower than in the untreated ones; a similar 
observation has been reported previously (Kawasaki et al, 2007). These data indicate 
that anle138b prolongs the incubation period of infection by inhibiting prion propagation 
in the brain.  
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Figure 33. Western blotting measured PrPres concentrations in the brains of 
different dpi. (a) Purified PrPres from 2 mg of brain of different dpi of treated and 
untreated mice were detected by immuonoblotting. PrP
C
 is the migration control on the 
left. Molecular weights are shown on the right. (b) The concentrations of PrPres in the 
brains (g/g) of 5 mice of each time points were measured by quantitative 
immunoblotting densitometrically. Significance of comparing PrPres quantitations of 
treated and untreated mice was calculated with the t-test (p = 0.006). 
 
 
To measure the accuracy of qRT-QuIC, PrPres purified from anle138b-treated and 
untreated mouse brains was serially diluted (10
-7
, 10
-8
, 10
-9
 and 10
-10
 g of brains, n = 5) 
followed by seeding into qRT-QuIC preparations. Profiles of detecting PrPres in 10
-10
 g 
brains with qRT-QuIC are shown in Figure 34 a to demonstrate the number of hours 
required to initiate reactions seeded with PrPres. Using the formula in Figure 27 c, 
PrPres equivalents were quantified and were converted to PrPres concentrations (g/g 
brain) with extrapolation to compare with quantities detected by Western blotting 
(Figure 34 b). Quantitation results from two methods did not show significant 
differences on measuring PrPres concentrations (p = 0.1276 for untreated groups and 
p = 0.5673 for anle138b-treated groups) indicating that qRT-QuIC provided accuracies 
comparable to Western blotting. Due to the extremely high sensitivity (Figure 27 a and 
b) as well as the reliable quantification, we argued that qRT-QuIC was competent to 
quantify the PrPres in materials containing minimal amounts of PrP
Sc
.  
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Figure 34. PrPres concentrations measured by qRT-QuIC are comparable to the 
results of Western blotting. (a) PrPres purified from 10
-10
 g of brains of different dpi 
was measured by qRT-QuIC. The required hours for measuring PrP
Sc
 concentrations 
are indicated on the top right. PK-digested 10
-10
 g of brains from uninfected mice was 
seeded as controls. (b) The PrPres equivalents from 10
-7
 g to 10
-10
 g of brain of 
different dpi from treated and untreated mice were measured by performing qRT-QuIC. 
PrPres concentrations in the brain (g/g) were calculated by extrapolation using the 
formula in Figure 27 c. Results of qRT-QuIC were compared to the results of Western 
blotting (IB) as shown in Figure 33 b. The significances were calculated by two-way 
ANOVA using the weight of used brains and dpi as the variables (p = 0.1276 for 
untreated groups and p = 0.5673 for treated groups). 
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4.4.2   Quantifying PrPres in the urine monitors anti-prion 
treatment 
The urine samples were harvested from the mice shown in Figure 33 b. To remove 
components potentially affecting qRT-QuIC, urine from both anle138b-treated and 
untreated mice (200 μl from each mouse) was purified following the procedure of 
isolating PrPres described in Material and Methods to receive ‘urine extracts’ which 
contains extremely low amount PrPres that was not visible on Western blots. The urine 
PrPres was seeded into qRT-QuIC reactions (Figure 35 a). For untreated mice, results 
showed that PrPres was detectable in the urine at both 120 and 170 dpi, but not at 80 
dpi. Interestingly, for anle138b-treated mice, PrPres was positive in the urine of 170 
and 250 dpi, whereas it was negative in 80 or 120 dpi. In particular, reaction seeded by 
urine extract from untreated mice of 170 dpi showed obviously shorter lag-times than 
other reactions. After performing 35 independent reactions (5 mice for each dpi), a total 
of 20 urine extracts were found positive in qRT-QuIC: from untreated mice of 120 and 
170 dpi, and from treated mice of 170 and 250 dpi (Figure 35 b). In these results, 
seeding activity of 5 urine extracts of each dpi showed high reproducibility (5/5 and 0/5), 
indicating high stability of detecting PrPres in the urine of RML-infected mice with 
qRT-QuIC. PrPres equivalents in urine extracts were quantified with qRT-QuIC formula 
in Figure 27 c followed by mathematical extrapolation to concentrations in the urine 
(g/ml) (Figure 35 c). The results showed that urine extracts from untreated mice of 170 
dpi had significantly higher PrPres equivalents than those from untreated 120 dpi (p = 
0.0007) and treated 170 dpi (p = 0.0002), while the later two had similar PrPres 
equivalents. However, urine extracts from anle138b-treated mice of 250 dpi showed 
slightly increased PrPres equivalents (p = 0.0547) comparing with those of treated 170 
dpi. These results indicate that anle138b interrupts not only the PrP
Sc
 formation in the 
brain, but also decreases the PrPres equivalents in the urine of prion-infected mice. 
This also implies a correlation of PrP
Sc
 concentrations of the urine and the brain. 
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Figure 35. Quantification of PrPres equivalents in the urine of mice treated with 
anti-prion compound anle138b and untreated mice. (a) 200 μl of mouse urine from 
80, 120, 170 dpi of untreated mice, and 80, 120, 170 and 250 dpi of mice treated with 
anle 138b were collected followed by preparing PK-treated urine extracts as the seeds 
for qRT-QuIC. The urine extracts of non-infected mice are the controls. (b) A total of 20 
positive reactions were observed while seeding prion-infected urine in qRT-QuIC. Each 
scale on the Y-axis represents one positive reaction. (c) PrPres equivalents in the urine 
(g/ml) were calculated by employing the formula in Figure 27 c. The significances were 
calculated using the t-test. Shown are mean and s.e.m. (n = 5). 
 
 
To see if the changes in the urine corresponded to the changes in the brain, PrPres 
equivalents of 1 ml of urine were divided by those of 10
-10
 g of brain from corresponding 
dpi to obtain the ratios (urine/brain, represented as u/b value). Equivalents from 120 
and 170 dpi of untreated mice, and those of 170 and 250 dpi of treated mice, were 
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chosen, since urine extract-seeded qRT-QuIC reactions were positive only in these 
four groups (Figure 36). The u/b values did not show significant differences in either 
the untreated (p = 0.4593) or treated group (p = 0.3985), indicating that alterations of 
PrPres equivalents in the urine are parallel to those in the brain. This corroborates the 
rationale of measuring PrPres in the urine to demonstrate the therapeutic effect of 
anti-prion treatment in vivo. 
 
 
 
Figure 36. Changes of PrPres equivalents in the urine corresponded to those in 
the brain. For each dpi, PrPres equivalents in 1 ml of urine were divided by the 
equivalents in 10
-10
 g of brain to obtain a ratio (urine/brain, u/b value). The potential 
differences of ratios were analyzed using the t test. Shown are mean and s.e.m. (n = 5) 
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5   Discussion 
5.1   Utilizing PMCA for screening anti-prion compounds 
In the study of screening anti-prion compounds for anti-prion therapy, I employed 
PMCA as one of the decisive steps before bioassays. The advantages of PMCA are 
evident from the work: i) it allows directly spiking compounds in a cell-free system to 
efficiently analyze their anti-prion activities to narrow down the library of candidates 
and indicate those promising options before time- and cost-consuming in vivo studies, 
ii) PMCA utilizes original brain homogenates as the substrates containing most of 
ingredients in brain, e.g., protein supply, small chemicals and lipids (Deleault et al, 
2003; Wang et al, 2010), which are reported to be the essential factors of prion 
propagation in vivo, thus, not only the inhibition performed by PMCA is in line with 
those by animal model, even the EC50 of compounds observed from PMCA assay is 
also comparable with that in vivo, iii) PMCA is adapted to prions of various species 
and strains (Castilla et al, 2008), thus it can estimate anti-prion efficacies for different 
strains and hosts, which is important for developing treatments for human patients, as 
clinical trials in humans are very time-consuming and limited by the low number of 
patients available for clinical trials. It is noteworthy that, the third advantage of PMCA 
may be the most important one. To my knowledge, the cell culture model of prion 
infectivity has only been established for the mouse-adapted scrapie prions. A cellular 
model for human prion, however, is not available so far. Transgenic mouse models of 
expressing human PrP
C
 have been established. Human prion incubation periods in 
these models are from 200 to 300 days (Wadsworth et al, 2008). Therefore, using 
PMCA to test the anti-prion ability of those drug-like candidates before animal and 
human tests is necessary.  
 
5.2   Tests of inhibiting prion propagation in vivo are essential 
Regarding treatment of prion diseases in humans, DPP-derivatives and specifically 
anle138b represent a new lead structure with several favorable features according to 
the in vivo assays. They are small molecules that have an excellent oral bioavailability 
and blood-brain-barrier penetration without signs of toxicity at therapeutic doses. To 
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the best of our knowledge, the prolongation of survival even in late-stage treatment 
experiments obtained in prion-infected mice is by far the largest that has been 
discovered for any drug-like compound tested so far. I did not observe a selection and 
over-representation of PrP
Sc
 species in treated animals indicating that there is no 
development of new resistant strains. However, none of these observations above 
can be addressed by in vitro studies. Several studies aiming at the development of 
new therapeutic anti-prion compounds could show anti-prion activity only in cell 
culture but lack data in animal models or compounds were found to be inefficient in 
vivo (Ghaemmaghami et al, 2010; Gallardo-Godoy et al, 2011; Thompson et al, 2011). 
For example, quinacrine was reported to exhibit a strong anti-prion activity in 
cell-culture (Korth et al, 2001). However, in vivo studies in mice and humans were 
unsuccessful (Collinge et al, 2009) as this compound does not reach sufficient 
concentrations in the brain (Gayrard et al, 2005), which underlines the importance of 
systematic and timely in vivo testing to optimize therapeutic efficacy of synthesized 
compounds not only in vitro but in vivo.   
 
5.3   RT-QuIC for diagnosing prion diseases 
The established RT-QuIC for diagnosing human CJD in CSF had received 100% 
sensitivity and 100% specificity. The results of blind tests were better than the data of 
published studies (Atarashi et al, 2011; McGuire et al, 2012). Further tests using 
different rPrP species to amplify various prion strains showed that one rPrP substrate 
may effectively amplify only a subset of PrP
Sc
, suggesting that selecting optimal rPrP 
substrate before performing clinical diagnosis of prion diseases is required.  
  
In previous tests from other laboratories, it was concluded that vCJD seed was not 
suitable in RT-QuIC since only hamster rPrP was used in these studies (Orrú et al, 
2009; Peden et al, 2012). Although human rPrP has been used for detecting human 
sCJD (Atarashi et al, 2011) but not vCJD, to gain 80% sensitivity from detecting 30 
blindly prepared human CSF, it was concluded that those RT-QuIC reactions 
containing human rPrP could only be monitored for 48 h due to the false-positive 
problem in these tests. One solution is to use serial RT-QuIC (oral presentation in 
JPND-Demtest meeting, 2012, Hannover, Germany), which involved serially 
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transferring RT-QuIC products from reactions of 48 h into freshly prepared human 
rPrP substrates similar to the principle of sPMCA mentioned in section 2.2.2 and 
Figure 3. Serial RT-QuIC may help to increase both the sensitivity and specificity. 
However, it will also retain the shortages of sPMCA, such as increasing the risks of 
cross-contamination and spreading the human prions with aerosol. I solved this issue 
of detecting vCJD PrP
Sc
 by inventing a new preparation of human rPrP and increasing 
the quality of mouse rPrP. My data indicate that reliable RT-QuIC substrates were 
developed for detecting human CJD and cattle BSE that may help to solve the threats 
for public health.  
 
Cautiously, given the large number of cases that needs to be diagnosed as prion 
diseases or other neurodegenerative disorders, we only picked up a tiny part of prion 
cases to establish this diagnostic technique. A greater number of cases, especially 
those cases with co-existence of prion disease with other fatal disease such as 
Alzheimer disease (AD), Parkinson disease and dementia with Lewy Body (DLB) that 
may lead to diagnostic problems, should be tested. Furthermore, more samples from 
livestock should be subjected to RT-QuIC in the future to gain a better understanding 
of how to apply this technique for not only human clinical validation but also safety 
assessments of food and other animal products.  
 
5.4  qRT-QuIC for quantifying PrPSc in prion-infected tissues 
I have developed quantitative RT-QuIC (qRT-QuIC) to quantify with high accuracy 
minute amounts of PrP
Sc
 in the brain and various peripheral tissues at levels far below 
detection by in vivo transmission. qRT-QuIC is based upon the quantitative correlation 
between the seeded amount of PrPres and the lag time to the start of the conversion 
reaction detected by RT-QuIC. By seeding known amounts of PrPres quantified by 
immunoblot into qRT-QuIC a standard calibration curve can be obtained. Using this 
calibration curve, seeded undetermined amounts of PrPres can be directly calculated. 
The qRT-QuIC allows quantifying PrPres concentrations at extremely low levels as 
low as 10
-15.5
 g PrPres, which corresponds to 0.001 LD50 units obtained by in vivo i.c. 
transmission studies. I have find that PrPres concentration increases steadily in the 
brain after inoculation and can be detected at various time points during the incubation 
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period in peripheral organs (spleen, heart, muscle, liver, kidney) in two experimental 
scrapie strains (RML, ME7) in the mouse.  
 
In a recent study, Wilham and colleagues (Wilham et al, 2010) used SD50 (50% 
seeding dose) to quantify seeding activity in the RT-QuIC. SD50 was defined as 
minimum seeded amount causing 50% of RT-QuIC reactions to be positive. Using 
end-point titration in a dilution series for quantification, SD50 was shown to correlate 
with the infectivity of 263K strains in hamster. To obtain SD50 values for one prion 
strain in RT-QuIC, serially diluted standard sample are required, e.g., serially diluted 
prion-infected reference brain homogenate and serially diluted undetermined 
materials. Thus, this approach requires multiple repetitions to yield the percentage of 
positive reactions for every dilution. In contrast, qRT-QuIC is a lag time-based assay 
and the amount of PrPres equivalents in suspected materials can be directly 
calculated and quantified with much fewer repetitions based on the calibration curve. 
The respective advantages and disadvantages of end-point titration and lag time 
assays are well known from assays of prion infection in vivo. End-point titration 
provides an accurate measure of infectious units. However, end-point in vivo assay 
also requires multiple repetitions for each dilution of seeds to obtain the titration of one 
prion strain, whereas the incubation time in vivo assay is more commonly used for 
prion quantification as much less animals are required. These drive to conclude that 
the qRT-QuIC assay is more suitable than SD50 measurements for quantitative 
detection and high-throughput assay for prion diagnosis.  
 
5.5   Monitoring anti-prion treatment by quantifying PrPSc in the 
urine 
Two strategies were normally applied to test anti-prion efficacy of drugs in previous 
studies: i) Tracking the progress of disease by measuring the PrP
Sc
 concentration in 
the brain at different dpi, ii) observing the survival time; a combination of i) and ii) is 
often applied. However, these methods require large numbers of animals for analyzing 
PrPres in the brain plus long-term experiments spanning the entire prion-incubation 
period. Furthermore, these strategies are impossible or difficult to apply in clinical trials 
of human prion disease. A recent study (Collinge et al, 2009) testing quinacrine for 
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anti-prion activity in humans showed 2 years of monitoring clinical features of treated 
patients without identifying the PrP
Sc
 states in materials, e.g., CSF, due to the lack of 
sensitive detection and quantification techniques to verify the appropriate 
concentration of drugs and to track the progression of disease for assessing anti-prion 
therapeutic effects. 
 
The sensitive and reliable qRT-QuIC enabling to monitor the efficacy of anti-prion 
treatment in living animals by using urine samples has been developed. By collecting 
urine for qRT-QuIC to monitor treatment instead of harvesting brains for WB during the 
prion-incubation period, two advantages can be seen: i) the required number of 
experimental animals for one treatment can be decreased significantly (Figure 37), 
which helps to minimize the costs and animal suffering; This advantage will be much 
more obvious when assessing anti-prion therapy in big animals (e.g., primates, elk, 
cattle and sheep). ii) qRT-QuIC as a rapid, sensitive and specific diagnostic method 
can provide a reliable assessment of anti-prion therapy in vivo that can be applied in 
humans. In addition, since the presence of prions has been identified in the CSF, blood, 
urine, saliva and feces of certain species (Brown et al, 1994; Saá et al, 2006; 
Mathiason et al, 2006; Tamgüney et al, 2009), these biological materials provide more 
options of seeds to monitor anti-prion therapy by quantifying PrPres, or PrP
Sc
, with the 
qRT-QuIC technique. 
 
 
 
Figure 37. The advantage of using qRT-QuIC to monitor the anti-prion treatment 
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in vivo. The common strategy is to harvest brains from experimental animals (mice) at 
several time-points for tracking changes of PrPres concentrations with, e.g., 
immunoblotting, for evaluation of anti-prion treatments. These experiments have to be 
performed with many groups of mice. Gray rectangles represent PrPres bands of 
diglycosylated, monoglycosylated and unglycosylated PrP, respectively, after 
PK-digestion and immunoblotting. Densities of PrPres bands correspond to increases 
of PrPres concentration in disease progression. However, using qRT-QuIC as the 
diagnostic tool to quantify PrPres equivalents in the urine, prion progression can be 
monitored in the living animals. Thus, the required number of experimental animals is 
much smaller than those in the top panel of the schematic. Thus, qRT-QuIC increases 
the efficiency of monitoring the progress of prion-infection and estimating therapeutic 
effects. The amplification of PrPres in the qRT-QuIC reaction is represented by red 
curves, the controls are depicted by green curves. 
 
 
Gabizon’s group was the first to report PrP
Sc
 in the urine of CJD patients and 
scrapie-infected hamster (Shaked et al, 2001), but their findings could not be 
reproduced by other groups by simply following the published protocol (Serban et al, 
2004; Furukawa et al, 2004; Head et al, 2005). However, scrapie could be transmitted 
by inoculating mice and sheep with urine of nephritic animals (Seeger et al, 2005) and 
with highly enriched urinary proteins from symptomatic prion-infected humans and 
animals (Haley et al, 2009; Notari et al, 2012). This suggested the authentic existence 
of prions, or PrP
Sc
, in the urine of scrapie or CJD-affected individuals, particularly those 
with simultaneous inflammatory kidney disease. However, the mechanism of PrP
Sc
 
amplification in the urinary system or shedding into the urine of animals is not 
understood at the moment.  
 
The time-span of qRT-QuIC in our experiments was fixed at 90 hours since longer 
duration may cause false positivity. A previous study has shown that RT-QuIC is stable 
up to 120 hours (McGuire, 2012) when choosing hamster rPrP to amplify CJD PrP
Sc
 in 
human CSF, since hamster rPrP is thought to be a suitable substrate for amplifying 
human PrP
Sc
 in QuIC (Orrú et al, 2009). In contrast, I used mouse rPrP as the 
substrate for quantifying mouse prion PrPres, since I found that mouse rPrP responded 
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rapidly to the triggered amplification by mouse PrPres. It is possible that using rPrP of 
other species may necessitate comparable or longer reaction times. 
 
In conclusion, I have utilized qRT-QuIC to monitor the treatment of the anti-prion 
compound anle138b by measuring the PrPres equivalents in the urine of prion-infected 
mice. Furthermore, qRT-QuIC can help to not only decrease the number of 
experimental animals, but also provide a technical improvement of assessing treatment 
in humans. Many more studies will be necessary before the understanding of the 
pathophysiology of PrP
Sc
 shedding into the urine. The technique may have drawbacks, 
e.g., it may be slow to visualize a trend such as prion amplification that is quick in the 
CNS, it may differ from species to species etc. Be that as it may, qRT-QuIC will open up 
a whole new avenue of anti-prion drug testing in the near future. 
 
5.6   Perspectives 
The presented studies have demonstrated that autocatalytic prion amplification in vitro 
can be utilized for the screening of anti-prion drug candidates, sensitive diagnosis of 
prion diseases, tracking disease progression and monitoring therapeutic effect of 
prions. Freshly prepared brain homogenates containing most of the brain-derived 
essential elements for the propagation of spiked prion in PMCA allow the elucidation of 
anti-prion activities of compounds, which provides an effective tool for drug testing 
before clinical trials in human. Meanwhile, highly efficient amplification of prion in 
RT-QuIC and qRT-QuIC allow for the rapid diagnosis and accurate quantification using 
small samples, which fulfills the need for measuring of disease progression with 
minimal injury on the individual. Based on the presented findings on PMCA, RT-QuIC 
and qRT-QuIC, two major lines of forthcoming research can be considered. On one 
hand, an investigation of the possibility of translating the achievement from the mouse 
model to human clinical trials should be performed. While the clinical validation is 
started, the CSF, blood and urine of the patient should be periodically collected for 
prion detection and quantification, the latter can serve to indicate disease progression 
and to monitor treatment response in case/control studies. Even without knowing the 
pharmacokinetic of the drug in human brain, qRT-QuIC can still assist the physicians to 
get a better assessment of therapeutic efficacy in prion-infected patients. The second 
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type of studies is related to enable drug screening in the context of basic and 
preclinical research. Although anle138b has demonstrated to be highly active for 
inhibition of prion propagation both in vitro and in vivo, the ultimate neutralization and 
cure of the disease is not settled. Developing new drugs based on anle138b will not 
only contribute to prion research, also provide manifold references to other protein 
disorder related diseases.  
 
Findings presented here suggest a suitable systematic procedure of prion treatment: 
first, selecting the most promising candidates with PMCA; second, using much fewer 
mice for in vivo test through monitoring therapeutic efficacy by quantifying urinary PrP
Sc
 
with qRT-QuIC; third, rapidly discriminating prion-infected patient at early clinical stage 
with RT-QuIC; four, treating patient with newly developed drug combined with 
estimating prion levels in samples easily obtained, e.g., urine, with qRT-QuIC. This 
procedure should significantly increase the efficiency of treatment development for 
prion disease both at the preclinical and at the clinical level. 
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7   Abbreviations 
AD Alzheimer disease 
ASA amyloid seeding assay 
BSE bovine spongiform encephalopathy 
C-BSE classical type bovine spongiform encephalopathy 
CJD    Creutzfeldt-Jakob disease 
CNS central nervous system 
CWD chronic wasting disease 
CSF cerebrospinal fluid 
DLB dementia with Lewy Body 
DMSO Dimethyl sulfoxide 
dpi day post inoculation 
DPP 3,5-diphenyl-pyrazole 
fCJD     familiar Creutzfeldt-Jakob disease 
EC50     half maximal effective concentration 
FFI      fatal familiar insomnia 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
L-BSE low type bovine spongiform encephalopathy 
LD50     half lethal dose 
MM      methionine/methionine homozygous at codon 129 aa of prion protein 
MM1     classified human case of Creutzfeldt-Jakob disease type 1 whose 
prion protein is methionine/methionine homozygous at codon 129 aa 
MV     methionine/valine heterozygous at codon 129 aa of prion protein 
MV2    classified human case of Creutzfeldt-Jakob disease type 2 whose 
prion protein is methionine/valine heterozygous at codon 129 aa 
NBB    N-benzylidene-benzohydrazide 
NIH     national institute of health 
NTA Nitrilotriacetic acid 
OD optical density 
PCR    polymerase chain reaction 
PD      Parkinson disease 
PK     proteinase K 
Abbreviations 
 
 
 
98 
PMCA    protein misfolding cyclic amplification 
PrP      prion protein 
PrP
C 
    normal cellular prion protein 
PrP
Sc
    abnormal scrapie-like prion protein 
PrPres   proteinase K-resistant prion protein 
PVDF    polyvinylidene fluoride 
qRT-QuIC    quantitative real-time quaking-induced conversion 
QuIC     quaking-induced conversion 
rPrP      recombinant prion protein 
rPrPres    proteinase K-resistant recombinant prion protein 
RFU      relative fluorescence unit 
RT-QuIC    real-time quaking-induced conversion 
SAR     structure-activity relationship 
sCJD    sporadic Creutzfeldt-Jakob disease 
SDS     sodium dodecyl sulfate 
SIFT     scanning for intensely fluorescent targets 
sPMCA    serial protein misfolding cyclic amplification  
ThT      thioflavin T 
TSEs    Transmissible spongiform encephalopathies 
vCJD    variant Creutzfeldt-Jakob disease 
VV      valine/valine homozygous at codon 129 aa of prion protein 
VV2    classified human case of Creutzfeldt-Jakob disease type 2 whose 
prion protein is valine/valine heterozygous at codon 129 aa 
WB    Western blot 
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